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TUBERCULOSIS INFECTION IN A MURINE MODEL 
Thorbjorg Einarsdottir, PhD 
University of Pittsburgh, 2010 
ABSTRACT 
Although more doses have been given of the tuberculosis vaccine (BCG) than any other vaccine 
in history, tuberculosis remains the second leading cause of death due to an infectious agent 
worldwide. Our understanding of the immune response to the bacterium is incomplete, which has 
partly been due to a lack of known bacterial T cell epitopes. In recent years, several epitopes 
have been identified, which has enabled the use of new reagents and assays to study T cell 
responses. Furthermore, development of recombinant bacteria expressing model antigens has 
facilitated the use of many more reagents and techniques, as well as allowing us to compare M. 
tuberculosis-specific T cell responses to those induced by other infectious agents. The aim of this 
thesis was to better understand the CD8 T cell response to M. tuberculosis and identify factors 
that regulate the response. We showed that, unexpectedly, the primary CD8 T cell response was 
more effective than the memory CD8 T cell response to M. tuberculosis, in that primary cells 
secreted higher levels of IFN- and were more cytotoxic. We also showed that cytotoxicity and 
secretion of IFN- were carried out by distinct M. tuberculosis-specific CD8 T cells, which 
indicates that there is a functional defect in these cells that is not seen in other infections. 
Contrary to chronic viral infections, however, M. tuberculosis-specific CD8 T cells did not 
appear to become exhausted, despite the chronicity of the infection. We further showed that the 
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function of CD8 T cells was influenced by various factors, such as interactions with pre-existing 
memory cells, the quality of CD4 T cell help and the environment that the cells were primed in. 
Manipulation of these factors can increase the quality of the immune response, giving 
multifunctional CD4 and CD8 T cells, as well as CD8 T cells capable of simultaneously being 
cytotoxic and secreting IFN-, without altering the bacterium. This indicates that modifications 
in delivery of tuberculosis vaccines may result in improved efficacy. The work presented may 
contribute to advances in the development of new tuberculosis vaccines, as well as improvement 
in efficacy of the existing vaccine. 
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1.0  INTRODUCTION 
1.1 HISTORY OF TUBERCULOSIS IN HUMANS 
Tuberculosis (TB) is primarily a lung disease, caused by Mycobacterium tuberculosis (M. 
tuberculosis), a bacterium that has coexisted with humans for millennia. The first records of M. 
tuberculosis causing disease in humans come from 9000 year old skeletal remains from Israel 
[1]. Rampant TB in the human population has been documented from the time of Hippocrates 
(around 400 BC) and M. tuberculosis was the cause of the white plague of the 18
th
 and 19
th
 
centuries [2, 3]. The TB pandemic was controlled to a great extent in developed countries 
through the development of antibiotics and improvement in public hygiene and nutrition, while 
the rate of infection remained high in less prosperous areas. TB received little attention until 
there was a resurgence in developed countries in the 1980s and 1990s, in part due to the spread 
of the human immunodeficiency virus (HIV) [4, 5]. In 1993 the World Health Organization 
(WHO) declared TB a global health emergency and since then a tremendous effort has been 
made to control the infection. Despite this, there are eight to ten million new cases of active TB 
annually. Approximately two million people die every year, making TB the second leading cause 
of death due to an infectious agent [6]. 
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1.2 INFECTION OUTCOME 
It is estimated that a third of the human population (approximately two billion people) is 
infected with M. tuberculosis, the majority (about 90%) of whom are able to contain the 
infection (termed latent infection) and show no signs of disease (Figure 1D and F). Induction of 
M. tuberculosis-specific adaptive immune responses (discussed in chapter 1.4) in these people 
yields a positive response to the purified protein derivative (PPD) skin test, although the skin test 
does not discriminate between persons latently harboring bacteria and those who may have 
eventually cleared the infection [7]. Vaccination with Bacille Calmette-Guerin (BCG, discussed 
in chapter 1.7.1) also induces a positive PPD skin test due to cross-reactive immune responses 
[8]. 
 
Figure 1 M. tuberculosis infection course in humans. 
People exposed to the bacterium (A) can clear the infection (B) or be colonized (C to F). 5-10% 
of persons develop primary TB within two years from infection (C), while the majority are able 
to contain the infection without clinical symptoms (D). About 10% of latently infected 
individuals lose control of the infection at some point and progress to active disease (E), while 
the remainder contains the infection life-long (F). Previous exposure to M. tuberculosis does 
not necessarily prevent re-infection (G). 
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About 5% of infected individuals are unable to contain the initial infection and progress 
to active TB within two years of infection, although this percentage is higher in young children 
and immunocompromised persons [2, 9, 10] (Figure 1C). In addition to a positive PPD skin test, 
these individuals show clinical symptoms such as cough, weight loss and positive bacterial 
cultures [11], although the specific symptoms can depend on the site of disease (discussed 
below). 
Of those who contain the initial infection and develop latent infection, there is a 10% life-
time risk of reactivation and progression to active TB (Figure 1E). For unknown reasons, the rate 
of reactivation is higher in adolescents and young adults than in other age groups [9]. 
Immunosuppression, e.g. due to HIV-infection, is also a strong risk factor for reactivation (10% 
annual risk of reactivation) [2, 10, 12]. Thus, while the majority of persons are able to contain 
the bacterial infection, there is an enormous reservoir of persons harboring bacteria and the 
infection can reactivate for no apparent reason, although factors such as immunosuppression, 
malnutrition, and age are strong risk factors [9]. 
To further complicate the scenario, the symptoms of TB can vary greatly, making the 
infection difficult to identify. Pulmonary TB is the most common form of disease, of which the 
hallmark symptom is coughing. However, the bacteria can infect and cause disease in almost any 
part of the body, such as the meninges, lymphatic system, genitourinary system and bones. Each 
site of disease can manifest in different symptoms, e.g. pain and inflammation in the respective 
area, but more common symptoms are weight loss, fatigue and fever [11, 13]. While 
extrapulmonary TB is less infectious than pulmonary TB (discussed in chapter 1.3.4), this form 
of disease is often more severe [9, 11]. The risk of developing extrapulmonary TB is higher in 
immunosuppressed people and young children compared to healthy adults [13]. 
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1.3 INNATE IMMUNE RESPONSE 
 M. tuberculosis bacteria are transmitted by aerosolized droplets that are expelled by 
persons with active pulmonary TB [2, 14]. Upon inhalation of these droplets, the bacteria are 
deposited in alveolar spaces where they can be phagocytosed by macrophages (Mɸ) and 
dendritic cells (DC) (innate immune cells) [15-17]. 
1.3.1 Phagocytosis 
 Bacteria can be phagocytosed by Mɸ and DC through a variety of receptors (reviewed in 
[18]). It has not been fully established what effect the route of internalization has on bacterial 
survival [19], although it can affect the phenotype of the phagocyte [20-22]. In some cases, the 
phagocytic cells can clear the bacteria [14] leaving no measurable trace of the infection, i.e. the 
person has a negative PPD skin test (Figure 1B). Other times, the bacteria are able to escape 
killing by the innate immune response and can replicate in the phagocytic vesicles. To 
accomplish this, the bacteria inhibit phagosomal maturation (i.e. acidification and fusion to 
lysosomes), an important antibacterial mechanism of the innate immune cells, while allowing 
fusion to early endosomal compartments containing iron and nutrients [23]. Phagosomal 
acidification is inhibited by exclusion of ATPases from the phagosome [24] while phago-
lysosome fusion is prevented by inhibiting maturation of the phagosome, e.g. by retention of 
Rab5 (an early endosomal protein) and exclusion of Rab7 (a late endosomal protein) [25]. 
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1.3.2 Recognition of infection 
 Although M. tuberculosis can inhibit killing by phagocytes, the infected cells can 
recognize the infection through binding of bacterial components (pathogen associated molecular 
patterns, PAMP) to pattern-recognition receptors (PRR), such as Toll-like receptors (TLR) and 
nucleotide oligomerization domain-like receptors (NLR). While TLR signaling in response to M. 
tuberculosis is the best characterized of the PRRs, the individual TLRs appear not to be essential 
for the host [26]. However, myeloid differentiation factor 88 (MyD88), the common adaptor 
molecule for the TLRs bound by M. tuberculosis components, is essential for host survival [27]. 
This indicates that the importance of individual PRRs may be masked by redundancy between 
them [28], but the phenotype of MyD88 deficient mice may also be due to its role in interleukin 
(IL)-1 receptor signaling [29]. 
 Binding of M. tuberculosis components to PRR matures the phagocytes, and induces a 
downstream signaling cascade leading to production of microbicidal effector molecules, such as 
reactive oxygen intermediates (ROI), reactive nitrogen intermediates (RNI) and antimicrobial 
peptides [30-33], although they are not sufficient to control the infection without involvement of 
the adaptive immune response [34]. PRR signals also lead to production of chemokines that 
recruit leukocytes to the site of infection [17] and cytokines that determine the type of adaptive 
immune response that is induced. 
1.3.3 Cytokines and chemokines of the innate immune cells 
Mɸ and DC express various cytokines in response to the bacterium [35-38] which 
influence the priming of the adaptive immune response. Inflammatory cytokines, such as IL-1, 
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IL-12 and tumor necrosis factor (TNF), promote a Th1-type adaptive immune response and are 
essential for control of the bacterium [39-41]. Other cytokines, such as IL-4 and IL-10, promote 
a Th2-type response that results in decreased control of the bacterium [42, 43]. The immature 
immune response of young children is thought to increase their risk of developing 
extrapulmonary TB by skewing the immune response towards a Th2-type response (reviewed in 
[9, 44]). In addition to Th1-type and Th2-type responses, a recently identified subset of T cells, 
called Th17, are induced in response to IL-23. During primary infection, there is an early influx 
of IL-17 producing cells [45], but they do not appear to be essential for bacterial control [46].  
The type of immune response induced by M. tuberculosis infection is influenced by 
factors such as bacterial components, some of which induce a Th1-type response while others 
induce Th2-type responses [38]. The resulting immune response is likely to be a mosaic, and the 
balance between the two determines the infection outcome. Parallel responses to other infectious 
agents can also influence the cytokines produced. Parasite co-infections have been implicated in 
reactivation of latent M. tuberculosis infection [47] as well as decreased efficacy of BCG 
vaccination [48, 49] by skewing the T cell response towards a Th2-type response. 
Although both DC and Mɸ can be infected with M. tuberculosis and can prime T cell 
responses (serve as antigen-presenting cells), there are differences in how the cells respond to the 
bacterium. While Mɸ remain phagocytic and do not migrate out of the lung [21, 50], DC lose 
phagocytic potential [50] and upregulate expression of CCR7 and CXCR4, chemokines needed 
for migration to secondary lymphoid organs [51]. DC also express higher levels of costimulatory 
molecules and major histocompatibility molecules (MHC), needed for priming of naive T cells 
[35, 52]. 
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DC and Mɸ responses also differ once T cells have been primed. Bacteria can replicate 
unhindered in both DC and Mɸ until they are activated by IFN- and TNF, secreted by Th1-type 
T cells. This allows Mɸ, but not DC, phagosomes to acidify and fuse to lysosomes, as well as 
increase the expression of RNI ([35], reviewed in [53]). The Mɸ are then able to kill intracellular 
bacteria, while activation of DC allows the cells to control bacterial expansion, but not kill them 
[35]. This indicates that Mɸ are specialized to kill bacteria, while DC bridge the gap between the 
innate and adaptive immune responses. 
1.3.4 Granulomas 
 Granulomas are formed in response to chronic antigen stimulation, where infected cells 
are surrounded by uninfected Mɸ and DC. Inflammatory cytokines and chemokines secreted by 
the infected cells can activate the uninfected cells, to make them refractory to the bacterial 
inhibition of phagosome acidification and their fusion to lysosomes [54, 55]. The uninfected Mɸ 
and DC are surrounded by a cuff of lymphocytes [56]. Granulomas benefit the host by enclosing 
the bacteria and preventing their spread, and failure to form or maintain the granuloma structure 
is thought to dramatically increase the risk of developing TB. However, granulomas can also be 
beneficial to the bacteria, which can survive in this hypoxic environment for decades [57-59]. 
 The spectrum of granulomas that are formed in humans ranges from calcified granulomas 
(where bacteria may be contained or eliminated) to necrotic granulomas that cause tissue 
destruction. If the tissue destruction is close to bronchi, bacteria can enter the airways and be 
transmitted by aerosolized droplets into the patient's environment (reviewed in [60]). This allows 
spread of the infection, and is the reason why pulmonary TB is more infectious than 
extrapulmonary TB. 
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 Formation of the granuloma is the result of a complex interplay of host- and bacterial 
interactions that is not fully understood. Recent work in the zebrafish model, discussed in chapter 
1.6.4, indicates that granulomas are formed through interaction between the bacteria and host 
innate immune responses, and that granuloma formation is beneficial to bacterial growth [61-63]. 
However, there are significant differences in the structures of granulomas in different models. 
Most notably, mouse granulomas are less structured than those seen in non-human primates and 
humans, and while TNF is required for both formation and maintenance of granulomas in mice 
[41, 64], TNF-depletion in non-human primates does not appear to affect granuloma structures 
[65]. However, while the granuloma structure is intact in TNF-depleted primates, TNF is 
important for control of the infection. This became apparent in patients undergoing therapy to 
decrease TNF-mediated inflammation in autoinflammatory diseases such as rheumatoid arthritis 
and Crohn's disease. Inhibition of TNF signaling in these patients greatly increased the risk of 
reactivation of TB and of developing extrapulmonary TB [66, 67]. While the effect of TNF-
inhibition may be pleiotropic, one possible effect is decreased cytotoxicity of CD8 T cells, 
discussed in chapter 1.4.1.2. 
1.4 ADAPTIVE IMMUNE RESPONSE 
Mature DC transport live bacteria to secondary lymphoid organs, where they can present 
bacterial antigens to the adaptive immune cells. While this transport appears to be important for 
dissemination of the bacterium [68], it is essential for priming of T cell responses [69-71] and a 
delay in dissemination correlates with decreased control of infection [69, 72]. 
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1.4.1 T cells 
Priming of T cell responses to M. tuberculosis is delayed compared to many other 
infections [73, 74]. However, this priming coincides with control of bacterial expansion [75], 
which emphasizes their importance in combating M. tuberculosis. After priming, T cells migrate 
to infected tissues to exert their effector functions (discussed below). T cell responses appear to 
be primed in the mediastinal lymph node (the lung-draining lymph node), as this is the tissue 
where effector function is first observed [72]. Studies using adoptive transfer of M. tuberculosis-
specific T cell receptor-transgenic CD4 T cells further support this conclusion, as the cells start 
to proliferate in the lymph node before appearing in the lungs [70, 71]. However, this model 
depends on transfer of non-physiological numbers of transgenic T cells, which can influence the 
behavior of the cells [76, 77]. 
1.4.1.1 CD4 T cells 
CD4 T cells are essential for control of the bacterium [78, 79]. This is underscored in 
HIV-infected persons, where loss of CD4 T cells is associated with drastically increased risk of 
reactivation of TB [12]. CD4 T cells are important producers of IFN-, whose production peaks 
around three to four weeks post-infection [80]. IFN- activates antigen-presenting cells, and 
boosts expression of MHC and costimulatory molecules, and is the most critical factor identified 
in M. tuberculosis control, as IFN--deficient mice succumb to the infection earlier than any 
other immuno-deficient mice [81]. In CD4 T cell-deficient mice, other cells can compensate for 
the lack of CD4 T cell-mediated IFN- by increasing production of the cytokine so that normal 
levels are reached by four weeks post-infection. However, this is not sufficient to save the mice 
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from death [79]. Thus, early production of IFN-, and possibly other functions of the CD4 T 
cells, are essential for the immune response against the bacterium. 
Recent work using Leishmania major indicates that vaccines that induce CD4 T cells 
capable of secreting multiple cytokines (IL-2+IFN-+TNF+, multifunctional cells) give better 
protection than vaccines that induce CD4 T cells with fewer functions [82]. This appears to hold 
true for viral infections as well [83, 84], but has not been definitively demonstrated for 
mycobacterial infections [85-87]. It has not been established which immune responses are 
associated with protection during M. tuberculosis infection in humans, as the only current 
intervention that significantly lowers the bacterial load is long-term therapy with antibacterial 
drugs. 
CD4 T cells also shape the CD8 T cell response by providing "CD4 T cell help" to DC, 
although the exact nature and requirement of this help are controversial and appear to depend on 
the infectious agent [88-91]. One of the outcomes of CD4 T cell help is activation of the DC, 
which is accompanied by increased expression of costimulatory molecules and cytokines, and 
results in improved priming of CD8 T cells. In M. tuberculosis infection, CD8 T cell responses 
can be primed in the absence of CD4 T cells [79], but they are less cytotoxic [92], indicating that 
CD4 T cell help is important for determining the quality of the CD8 T cell response. 
CD4 T cells can also dampen the immune response, either by secreting anti-inflammatory 
cytokines such as IL-10 and transforming growth factor-β (TGF-β) [93], or through a mechanism 
requiring cell-cell contact [94]. These regulatory T cells, termed Tregs, attenuate the immune 
response to the bacterium, resulting in decreased inflammation [95] and a decrease in 
proliferation and effector function of T cells [96]. The literature indicates that Treg-mediated 
regulation of the immune response may be either beneficial [97] or detrimental [95, 98, 99] for 
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control of mycobacterial infection. More likely the answer lies somewhere in between, where a 
balance is struck between induction of immune responses, that can kill or control the bacteria, 
and suppression, that minimizes collateral damage (pathology) to the host. 
1.4.1.2 CD8 T cells 
Little is known about the role of CD8 T cells during M. tuberculosis infection. One 
reason is the dearth of known M. tuberculosis epitopes recognized by CD8 T cells [100]. In 
recent years, several M. tuberculosis-specific CD8 T cell epitopes have been identified [101, 
102], enabling the use of numerous new techniques to measure CD8 T cell function, discussed in 
chapter 3. Furthermore, successful development of recombinant strains expressing exogenous 
epitopes [103] has allowed us to manipulate the mouse infection model to previously 
unprecedented levels to ask specific experimental questions, discussed in chapters 4 and 5. 
One consequence of the high frequency of individuals co-infected with HIV and M. 
tuberculosis is that much has been learned about the role of CD4 T cells during M. tuberculosis 
infection. HIV-mediated depletion of CD4 T cells dramatically increases the risk of reactivation 
of TB [12], which confirms murine data on the importance of CD4 T cells in the control of 
infection [79]. We do not have a similar model of acquired CD8 T cell depletion in humans. 
However, CD8 T cell depletion in non-human primate models leads to rapid loss of control of 
the infection, which confirms the importance of CD8 T cells in TB ([104], Philana Ling Lin and 
JoAnne Flynn, unpublished results). This is not mirrored in the murine model [81], where CD8 T 
cells have a limited impact on the control of infection, observed mostly during chronic [78] and 
high-dose infections [105, 106]. However, the impact of CD8 T cells on bacterial load can be 
increased in mice through interventions such as DNA vaccines [107]. 
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Thus, while the availability of immunological reagents and different mouse strains make 
the murine model exquisitely useful for basic research and discovery (discussed in chapter 1.6.1), 
the results need to be verified in other models that better represent humans. Alternatively, using 
"humanized" mice, i.e. mice that have been genetically altered to express certain human proteins, 
may give a more faithful picture of the human immune response. One such example is a mouse 
strain expressing granulysin, an antimicrobial protein that is stored in cytolytic vesicles. 
Granulysin can kill M. tuberculosis, and its expression correlates with protection against TB in 
humans [108, 109]. It will be interesting to see whether CD8 T cells expressing granulysin are 
better able to control the infection than CD8 T cells from wild-type (WT) mouse strains. 
It is thought that the major role of M. tuberculosis-specific CD8 T cells is to eliminate 
infected cells that have become refractory to activating cytokines, such as IFN- [110]. The 
bacteria can then be taken up by uninfected Mɸ, which are still sensitive to IFN- and can better 
contain the bacteria [111]. While the importance of CD8 T cell-mediated cytotoxicity in mice is 
debated [112-114], it appears that cytotoxicity is important for control of TB in humans. It was 
recently shown that anti-TNF treatment decreased CD8 T cell mediated cytotoxicity in humans, 
by reducing the expression of perforin and granulysin [115]. This may be a mechanism of 
increased risk of reactivation of TB in patients undergoing anti-TNF treatment. 
CD8 T cells can also secrete cytokines, such as IFN- and TNF, which help to activate 
Mɸ and DC, although mouse CD4 T cells appear to produce sufficient cytokines to contain the 
infection. It has been suggested that multifunctional CD8 T cells, i.e. cells secreting IFN-, IL-2 
and TNF, may be more protective than cells with fewer functions [116]. However, very few M. 
tuberculosis-specific CD8 T cells appear to be multifunctional in humans [87] and non-human 
primates (Joshua T. Mattila and JoAnne Flynn, unpublished results). The impact of CD8 T cell-
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mediated cytokine secretion in control of TB in humans and non-human primates is unknown. 
However, due to the importance of IFN- for control of TB, a vaccine that induces strong CD8 T 
cell-mediated cytokine production could benefit individuals co-infected with HIV and M. 
tuberculosis, where CD4 T cell-mediated secretion may be compromised. 
1.4.2 Other cells 
 In addition to the cells discussed above, several other cell types respond during M. 
tuberculosis infection, although their role in controlling the bacterial infection is controversial. 
Examples include natural killer cells (NK), unconventional T cells (e.g. CD-1 restricted T cells 
and γδ T cells) and B cells. The B cell response illustrates the difficulty of establishing the role 
of the cells in controlling M. tuberculosis infection. During M. tuberculosis infection in both 
humans and mice, B cell responses have been shown to be protective [117], detrimental [44, 118] 
or contribute little to the infection outcome [119, 120]. It has also been suggested that B cells 
function in an antibody-independent manner, e.g. by presenting antigens to T cells [121], 
influencing the cytokine environment [117] or as a structural component needed for maintenance 
of the granuloma [118]. Thus, it remains to be conclusively established what role B cells play in 
control of infection. 
1.5 TREATMENT OF TB 
Before the development of effective TB drugs, the main approach to treating TB was to 
sequester patients in sanatoria. TB drugs, discovered between the 1940s and 1960s, enabled 
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clearing of infection, which greatly reduced infection rates as well as mortality and morbidity. 
Initially, recommended treatment duration was 24 months to ensure complete clearance of the 
bacteria [122], but subsequent advances have shortened the treatment to approximately 6 months 
[13]. While it is not fully understood why it takes so long to clear the bacteria, a granuloma-
induced state of nonreplication and metabolic inertia is believed to make at least a subset of the 
bacteria phenotypically resistant to many drugs [123, 124]. In addition, noncompliance due to the 
long treatment duration and toxicity has led to increasing drug resistance of the bacterium [13], 
severely limiting treatment options for patients. 
Despite pressing need for new TB drugs, no new first-line TB drugs have been added to 
the drug repertoire for the last 30 years [125]. In recent years, better understanding of the 
bacterium has led to the identification of several new drug candidates, some of which have 
reached clinical trials [123, 126]. 
1.5.1 Drugs from the 1940s 
Streptomycin (SM), an inhibitor of protein synthesis in replicating bacteria, was 
discovered in 1944 and was the first drug to be used against TB [127, 128]. The same year, para-
amino salt of salicylic acid (PAS), which likely inhibits bacterial cell-wall synthesis, was 
discovered to be effective against TB [127, 129]. In 1950 the British Medical Research Council 
published a paper showing that a two year regimen combining both drugs was more effective and 
decreased the risk of development of drug resistance compared to treatment with either drug 
alone [122, 130]. Both drugs are currently considered second-line TB drugs because of their 
toxicity [122, 124]. 
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1.5.2 Drugs from the 1950s 
Isonicotinic acid hydrazide (INH), which is thought to be an inhibitor of cell wall 
synthesis in replicating bacteria, was discovered in 1952 [129]. When added to the combination 
therapy of SM and PAS, this was more effective at clearing bacteria, and further decreased the 
risk of development of drug resistance [122]. Despite some toxicity associated with the drug, 
especially in HIV infected persons [124], INH is a first-line TB drug and is often 
prophylactically administered to people who are believed to be latently infected or have been 
exposed to persons with active TB [129]. 
Pyrazinamide (PZA) is another first-line drug that was shown to be effective against TB 
in 1952 [131], although the mechanism of action is unknown. 
1.5.3 Drugs from the 1960s 
Ethambutol (EMB), a metabolic inhibitor of replicating bacteria, was discovered in 1961 
[129]. This drug replaced PAS in treatment regimens, as it reduced both toxicity and the duration 
of treatment to 18 months [122]. 
Rifampin (RIF), an RNA transcription inhibitor, was discovered in 1966 [129]. When 
added to INH, SM and EMB treatment regimens, RIF reduced the duration of treatment from 
eighteen months to about nine months. It was shown in the 1980s that adding PZA, a drug that 
was discovered in the 1950s, to INH and RIF treatment regimens could shorten treatment to as 
little as 6 months [122, 127]. 
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Both EMB and RIF remain first-line drugs, but unfortunately RIF can interact with 
antiretroviral drugs, causing their rapid break-down. This complicates the use of the drug in 
HIV-infected persons [123]. 
1.5.4 Directly Observed Treatment (DOT) 
The DOT treatment regimen was developed in 1959. DOT is a treatment strategy aiming 
at improving patient adherence, in which a person, such as a health-care provider or community 
volunteer, directly observes the patient taking their medicine. This has allowed patients to 
undergo treatment at home, instead of being isolated in sanatoria, away from their families for a 
year or more [127]. 
The treatment regimen has since been modified to Directly Observed Treatment, Short-
Course (DOTS), a 6 month treatment course aimed at further improving patient adherence. The 
standard DOTS regimen has two phases. First is a daily four-drug intensive phase for two 
months, followed by a two to three times per week, two-drug continual phase for four months 
[123, 132]. The drug combinations and durations depend on bacterial drug susceptibility and 
how the patient responds to treatment, as well as the patient's history of infection. 
1.5.5 Drug resistant bacteria 
The current first-line drugs are INH, RIF, EMB, PZA and a rifamycin. Multidrug-
resistant strains (MDR-TB) are defined as bacteria that are resistant to at least INH and RIF, 
while extensively drug-resistant strains (XDR-TB) are bacteria that are resistant to INH, RIF, a 
fluoroquinolone and at least one second-line injectable drug [14, 122]. Treatment of MDR-TB 
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and XDR-TB patients requires alternative drugs, many of which have severe side effects and 
have limited efficacy, and the treatment course is long [13]. Development of new TB drugs is 
believed to be especially beneficial to these individuals, many of whom have few or no 
alternative options. 
1.5.6 New drugs 
The Global Alliance for TB Drug Development, in collaboration with pharmaceutical 
companies, has three drugs in clinical trials, discussed below. All three drugs have a novel 
mechanism of action, which makes them exciting prospects for treating MDR-TB and XDR-TB 
patients who are resistant to other available drugs. 
PA-824 is in phase II clinical trials. The drug kills both replicating and non-replicating 
bacteria by inhibiting cell-wall synthesis and causing respiratory poisoning through nitric oxide 
release, respectively [133]. The drug does not appear to interact with antiretroviral drugs [123]. 
TMC207 is in phase II clinical trials. The drug kills both replicating and non-replicating 
bacteria by inhibiting the mycobacterial ATP synthase [134]. Interaction with antiretroviral drugs 
is currently being tested. 
Moxifloxacin is in phase III clinical trials. The drug kills replicating bacteria by 
inhibiting DNA gyrase [135]. This drug may be useful to significantly shorten the duration of 
treatment [136]. It does not appear to interact with antiretroviral drugs [137], making it useful for 
treatment of patients infected with HIV. 
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1.6 ANIMAL MODELS OF TB 
There is great heterogeneity within the human population in the response to M. 
tuberculosis, ranging from life-long control, to intermittent lapse in control or active disease 
[138, 139]. There is also heterogeneity within individuals, who may harbor different types of 
granulomas within the same lung lobe [140], indicating a spectrum of bacterial control. 
Mycobacteria can infect and cause disease in a wide range of animals [141], yielding an 
extensive selection of animal models in which to study the bacteria and their interactions with 
the hosts. Each animal model, some of which are mentioned below, reflects a particular aspect of 
human TB, and the suitability of the model depends on the experimental questions being asked. 
1.6.1 Mouse 
The mouse model is the most widely used in TB research. Although all mice are 
susceptible to M. tuberculosis, there are differences in susceptibility between mouse strains. 
C57BL/6 is the most commonly used mouse strain and is the most resistant, while C3H and 
DBA/2 are the most susceptible [142]. 
Like most humans, C57BL/6 mice are able to control M. tuberculosis and do not show 
signs of disease for one to two years. However, while humans have a low bacterial load and 
develop latent infection, mice have a high bacterial burden that causes a chronic progressive 
disease. This characteristic makes the mouse model particularly useful to study the effects of 
chronic antigen exposure on T cell function [139, 143]. Mouse granulomas lack the structural 
organization and caseous necrosis that are the hallmarks of human granulomas. Although the 
granulomas still serve to contain the infection, differences in their composition are likely to 
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affect the environmental conditions in the granuloma, such as the availability of oxygen and 
nutrients [126, 144]. 
The Cornell mouse model was developed to replicate human latent infection in mice. In 
this model, mice are treated with antibiotics to artificially simulate the paucibacillary state of 
humans [145]. There have been various alterations of the model, ranging from the infection route 
and inoculum dose to the duration of drug treatment [139]. While other animal models, such as 
rabbits, reflect human granulomas and latent infection better than mice, the mouse model has the 
advantage of being inexpensive, easily housed and manipulated, with a plethora of 
immunological reagents and mouse strains available [138]. 
1.6.2 Rabbit 
Rabbits are relatively resistant to M. tuberculosis infection and eventually heal their 
lesions [146], although more virulent strains of M. tuberculosis can cause progressive disease 
[147]. Due to their resistance to M. tuberculosis, rabbits may be a good model for studying latent 
TB [139]. 
In contrast to M. tuberculosis, rabbits are highly susceptible to M. bovis, which induces 
pulmonary pathology similar to that seen in humans [138]. The structure of rabbit granulomas is 
similar to that of humans, and has both caseous necrosis and cavity formation [139, 143]. Cavity 
formation allows the bacterium access to the external environment, which increases the risk of 
bacterial transmission [139]. 
Rabbits are fairly expensive to house, due to the risk of disease transmission and space 
requirements [139, 143]. Furthermore, there are relatively few immunological reagents available, 
which limits their use as an animal model for TB. 
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1.6.3 Guinea pig 
Guinea pigs are highly susceptible to M. tuberculosis. This animal model has been used 
to study the efficacy of antimycobacterial drugs and vaccines [148, 149], as vaccines and drugs 
need to be protective in a very susceptible host. 
Guinea pig granulomas have similar organization and caseous necrosis as human 
granulomas, but unlike human granulomas they lack cavitation and are unable to control 
bacterial expansion, making them a useful model for dissemination and secondary granuloma 
formation characteristic of an unsuccessful host response [139, 143, 150]. 
There is a certain lack of immunological reagents for guinea pigs, but the benefits of the 
model include guinea pigs being relatively inexpensive and easy to house in a biosafety level 3 
facility (BSL3) [150]. 
1.6.4 Fish 
 Goldfish and zebrafish have been used to study TB pathogenesis using M. marinum, a 
close relative of M. tuberculosis. For the first three weeks, fish embryos are transparent and have 
not yet developed an adaptive immune response [151, 152], allowing for real-time study of 
interaction between the pathogen and the innate immune response. Fish granulomas have a 
caseous center, which is a hallmark feature of human granulomas [152]. While there are still few 
immunological reagents available for fish, genetic and imaging tools have established this as a 
superb model for studying early events that are inaccessible in other models [151]. 
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1.6.5 Non-human primate 
Of all available animal models, the non-human primate immune response is the closest to 
the human response. The animals reproduce the full scale of human disease from latent infection 
to active disease and can transmit the bacterium as a human would [139]. Furthermore, they 
develop a spectrum of granulomas similar to that seen in humans [141, 153, 154]. The non-
human primate model is the only animal model that faithfully represents latent TB and can be 
used to study both natural and induced reactivation of latent TB. This model is also the only 
model available for studies of M. tuberculosis and HIV co-infection, and it has been used to 
study the efficacy of antimycobacterial drugs and vaccines [143]. 
There are many immunological reagents for non-human primates available, and owing to 
the close evolutionary relationship between humans and non-human primates, many human 
immunological reagents can be used as well. However, the animals are very expensive to 
purchase and house, and owing to the genetic variability of the non-human primates, the host 
response to the bacterium can vary greatly. While this makes it more difficult to identify trends 
in immune responses, it reflects the diversity of the human population and spectrum of likely 
immune responses. 
1.7 VACCINES 
As stated above, antibiotic treatment of M. tuberculosis is long and difficult, especially 
MDR-TB and XDR-TB strains where there are few treatment options. As infected people display 
a spectrum of symptoms or are asymptomatic, determining who should be treated and for how 
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long can also be difficult. The most practical and effective strategy to TB control would be to 
prevent establishment of infection through an efficient vaccine. However, immune responses 
induced by previous exposure to mycobacteria, whether they are virulent or not, are not 
sufficient to prevent re-infection. Thus, an effective vaccine would ideally elicit a better immune 
response than what is induced by natural mycobacterial infection [125]. 
For the last 88 years, BCG (discussed below) has been the gold-standard vaccine, with 
over 3 billion doses administered [155]. Better understanding of M. tuberculosis and its 
pathogenesis have led to the development of new vaccine candidates, some of which have 
reached clinical trials (discussed below). 
Some of the vaccines being developed are aimed at replacing BCG (pre-exposure 
vaccines). However, BCG is an important factor in limiting severe disease in children and cannot 
ethically be withheld. Thus, a new vaccine will have to be tested in conjunction with BCG and 
confer significantly more protection in order to be considered as a replacement for BCG. Other 
vaccines are aimed at boosting immune responses (post-exposure vaccines). 
The efficacy of TB vaccines is measured as absence of disease. However, only a small 
portion of people progress to overt disease, and this progression can occur decades after the 
initial infection. Thus, testing vaccine efficacy involves large cohorts and a time-span of decades. 
1.7.1 BCG 
 BCG is an inexpensive, live vaccine that was developed by serial passing of M. bovis for 
13 years [15]. During this time, the bacteria lost several genetic loci and became attenuated. The 
vaccine is given intradermally to infants in TB-endemic areas soon after birth and has been 
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shown to protect children by decreasing the risk of severe, often fatal, childhood forms of 
disease. However, the vaccine does not prevent infection with M. tuberculosis. 
 Efficacy in adults is variable, ranging from 0-80% protection against pulmonary TB [122, 
125, 156, 157]. Exposure to environmental mycobacteria, which induces cross-reactive immune 
responses, has been hypothesized as a reason for the variable efficacy of BCG [157, 158]. BCG 
needs to replicate and disseminate in the host in order to confer protection, but pre-existing 
immune responses to mycobacteria can result in rapid clearing of the bacteria [15]. BCG 
vaccination of adults in order to boost the immune response to mycobacteria has proven 
unsuccessful, presumably because pre-existing memory responses to M. tuberculosis, BCG or 
environmental mycobacteria rapidly cleared the vaccine [159, 160]. However, if BCG-induced 
memory responses can clear the vaccine, but not prevent infection or disease, this indicates that 
the vaccine efficacy is limited to begin with. 
1.7.2 Recombinant BCG 
 The virulence of the BCG::RD1 recombinant BCG strain was increased by adding back 
the Region of Difference 1 (RD1), a genetic region that was lost during attenuation of M. bovis. 
This strain is more protective than the parental BCG strain in mice and guinea pigs [161, 162]. 
However, increased virulence may make this vaccine unsafe, especially in areas where HIV-
induced immunosuppression is common and the need for improved vaccines is the greatest. The 
same argument holds true for attenuated strains of M. tuberculosis that are being developed as 
vaccine candidates, where the risk of reversion to increased virulence is likely to prevent 
widespread use of the vaccine [163]. 
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Another recombinant BCG vaccine strain being developed, rBCG::ureC-llo
+
, has 
decreased virulence compared to the parental strain [164], which may improve safety of the 
vaccine in HIV-infected individuals. The bacteria lack urease, which prevents them from 
arresting maturation of the phagosome. The bacteria express listeriolysin O (LLO), which is 
activated by the low pH of the mature phagosome. LLO damages the phagosomal membrane, 
allowing increased escape of the bacteria and bacterial antigens into the cytosol, which may 
improve priming of M. tuberculosis-specific CD8 T cell responses [164, 165]. This vaccine 
strain is scheduled to enter Phase I clinical trials. 
1.7.3 Viral vectors 
 Viral vectors can induce strong cell-mediated immune responses without adjuvants [156]. 
The Modified Vaccinia Ankara virus expresses antigen 85A (MVA85A), an immunodominant 
mycobacterial antigen that is present in BCG as well as M. tuberculosis [166]. The MVA85A 
vaccine induces strong immune responses in humans [85] and is more protective than BCG in 
mice [167]. However, one disadvantage of using this vector is that some people may have pre-
existing antibodies against the viral vector due to its use in other vaccines [168, 169], which 
could affect vaccine efficacy [170]. The MVA85A vaccine has entered Phase IIb clinical trials, 
the furthest of all new TB vaccines, and is one of the most promising novel vaccine candidates. 
The AERAS-402 vaccine is an adenovirus-based vector that expresses a fusion protein of 
M. tuberculosis-derived antigen 85A, 85B and TB10.4. The vaccine backbone is adenovirus type 
35, as pre-existing immune responses to it are relatively low [171], but as with the vaccinia-
based vector, this vector is also being developed for use against several other diseases [172, 173]. 
This vaccine is currently in Phase II clinical trials. 
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1.7.4 Recombinant protein vaccines 
 Recent advances in adjuvant development have been crucial to advancing development of 
recombinant protein vaccines [156]. One of the most important advantages of using recombinant 
protein vaccines is that they are not based on an infectious agent, and thus are likely to be safer 
for immunocompromised individuals. Immune responses are induced against specific highly 
immunogenic antigens; Mtb32 and Mtb39 in the GSK M72 vaccine [174], and ESAT-6 and 
antigen 85B in the SSI HyVac4 vaccine [175]. 
 Protection against M. tuberculosis is likely to require concerted immune responses 
against a wide range of antigens [125]. Thus, the narrow range of immune responses induced by 
both recombinant protein vaccines and viral vectors is likely to limit these vaccine strategies to 
post-exposure vaccines. GSK M72 and HyVac4 are currently in Phase II and I clinical trials, 
respectively. 
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2.0  STATEMENT OF THE PROBLEM 
The goal of this study was to investigate the function and regulation of CD8 T cells 
during M. tuberculosis infection in mice. This cell subset has received relatively little attention 
from TB researchers, as it has a smaller impact on the control of infection than CD4 T cells in 
mice. Recent work, however, has shown that CD8 T cells have an essential role in controlling the 
infection in non-human primates, a much superior model for human TB. Interest has been 
reawakened in CD8 T cells, and TB vaccine development is increasingly targeting this cell type. 
However, little is known about the function of the cells and what would constitute a protective 
CD8 T cell response. 
Infection with M. tuberculosis or vaccination with BCG leaves a person with memory 
CD4 and CD8 T cells that appear to be unable to prevent further infection. This indicates that in 
order to achieve a sterilizing vaccine (i.e. a vaccine that clears the bacteria or prevents 
establishment of infection) a different vaccine vector or alteration of the bacterial vaccines may 
be needed. However, as we don't know which T cell functions are desirable, this approach is "hit-
or-miss". A better understanding of what shapes the immune response and identification of a 
protective phenotype of T cells could provide "an end to a means", i.e. a specific phenotype for 
vaccine candidates to induce. 
We hypothesized that the function of M. tuberculosis-specific CD8 T cells induced 
during natural infection was not optimal, and that the function of the cells could be altered by 
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changing the environment that the cells develop in. To accomplish the work presented in this 
thesis, we generated a recombinant M. tuberculosis strain that expresses ovalbumin epitopes (M. 
tuberculosis-ova). This allowed examination of ova-specific CD4 and CD8 T cell responses in 
mice, and enabled us to use the plethora of ova-specific reagents available. Using this bacterial 
strain, we first studied CD8 T cell responses induced during primary and secondary infections 
(chapter 3). Next, using a strategy of WT M. tuberculosis infection followed by M. tuberculosis-
ova infection, we examined the function of primary CD8 T cells induced in the presence of 
memory cells (chapter 4). To examine the effect that the environment has on the function of T 
cells, we adoptively transferred ova-specific CD4 and CD8 T cells into mice at different times 
post-infection (chapter 5). Finally, we examined the effect of an inhibitory molecule, Qa-1, on 
CD8 T cell responses (chapter 6). 
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3.0  CYTOTOXICITY AND SECRETION OF IFN- ARE CARRIED OUT BY 
DISTINCT CD8 T CELLS DURING M. TUBERCULOSIS INFECTION 
This chapter has been adapted from a published study (Einarsdottir, T., et al., Cytotoxicity 
and Secretion of Gamma Interferon are Carried Out by Distinct CD8 T Cells during 
Mycobacterium tuberculosis Infection. Infect. Immun., 2009. 77(10): p. 4621-4630) with 
permission from the editor. 
3.1 INTRODUCTION 
M. tuberculosis, the pathogen causing TB, is an escalating global health threat that is 
spread between people by aerosolized droplets. While a subset of people develop primary disease 
and are infectious, most people contain the infection through a successful immune response 
(Figure 1). Typing of M. tuberculosis strains has shown that people can be infected 
simultaneously or sequentially with different strains of M. tuberculosis [176, 177]. Thus, 
immune responses that are sufficient to contain an initial infection may be unable to prevent 
establishment of subsequent M. tuberculosis infections. In addition, persons treated for TB with 
antimycobacterial drugs can be re-infected and develop disease [178]. This is true in animal 
models as well [179-181]. This suggests that memory responses generated during previous 
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mycobacterial infections are not generally capable of protecting against new infections or 
disease. 
It is currently unknown which, if any, immune functions can protect against 
establishment of infection. In terms of T cell responses, IFN- and TNF can activate infected Mɸ 
to induce antimicrobial activity, while cytolysis of infected cells can kill the bacterium or release 
it to be taken up by healthy cells that are better able to contain it [182, 183]. Most studies on the 
role of CD8 T cells during M. tuberculosis infection have focused on either IFN- secretion or 
cytotoxicity. A few studies have examined both functions, but not on a single cell basis [184-
186]. These studies indicated that CD8 T cell mediated IFN- secretion and cytotoxicity peak in 
lungs at four weeks post-infection. IFN- secretion subsequently decreases, while the results 
differ as to whether cytotoxicity decreases. This difference may be due to variation between 
mouse strains and epitopes, or the techniques used to assess cytotoxicity. 
In the current study, we demonstrate that most M. tuberculosis-specific CD8 T cells 
generated during primary infection were limited to either secretion of IFN- or cytotoxic 
function. There was a higher fraction of CD8 T cells with cytotoxic potential compared to those 
that produced IFN-. The CD8 T cell memory response was similarly exclusive in function. 
Despite increased degranulation, cells responding during secondary infection were less cytotoxic 
than cells responding during primary infection. Induction of superior quality CD8 T cells may 
provide benefit during M. tuberculosis infection, but a more detailed understanding of the 
complex T cell response to M. tuberculosis is necessary for the development of future preventive 
and therapeutic strategies. 
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3.2 MATERIALS AND METHODS 
3.2.1 M. tuberculosis-ova cloning 
The culture filtrate protein 10 (CFP10) gene (Rv3874, 225 bp) and 228 bp upstream 
sequence containing the CFP10 promoter were PCR amplified from M. tuberculosis genomic 
DNA and cloned into the pJL37 cloning vector [187]. An 87 bp ovalbumin (ova) gene fragment 
containing OTI- and OTII-recognized epitopes was PCR amplified from a larger fragment and 
cloned into pJL37-CFP10. Restriction enzymes (Roche, Indianapolis, IN) and T4 DNA ligase 
(Invitrogen, Carlsbad, CA) were used, according to manufacturers’ protocols. Plasmids were 
transformed into DH5 cells (Invitrogen) by 42˚C heat shock for 30 seconds and purified with 
High Pure Plasmid Isolation Kit (Roche), according to manufacturer’s protocols. The CFP10-ova 
insert was cloned into pMH94 integration vector [188] and electroporated [189] into M. 
tuberculosis Erdman strain (originally obtained from the Trudeau Institute, Saranac Lake, NY), 
using a Gene Pulser II (Bio-Rad, Hercules, CA). pJL37 and pMH94 plasmids were kindly 
provided by Graham Hatfull. 
3.2.2 PCR 
AccuPrime (Invitrogen), with primers from Integrated DNA Technologies (Coralville, 
IA) was used for PCR (95ºC [20sec], 45ºC [30sec], 68ºC [1min], 32 cycles, 68ºC [7min]), unless 
otherwise stated. 
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3.2.2.1 Primers for PCR amplification of CFP10  
CACCTCTAGAGCTCGCGCAGGAGCGTGAAGAAG (sense, CFP10-XbaI 5’), 
TATACATATGGAAGCCCATTTGCGAGGACAGCG (antisense, CFP10-NdeI 3’). 
3.2.2.2 Primers for PCR amplification of large ova fragment 
Overlapping primers were designed with UpGene DNA Codon Optimization Algorithm 
[190]. The primers were annealed and amplified at 94ºC (30 sec), 52ºC (30 sec), 72ºC (30 sec), 
55 cycles. 
AACCGGGATCCGGCTCGGAGC (s1), TAATGAATTCTCAGTGATGGT (as1), 
AGCTGGAGAGCATCATCAACTTCGAGAAGCTGGGCTCGGAGT (s2), 
GGTGGTGGTGGCCGCAGGTGGCGAAGTTGTACACGGCCTCG (as2), 
CGCTGAAGATCTCGCAGGCCGTGCACGCCGCGCACGCCGAGA (s3), 
AGCCGCGGCCGGCCTCGTTGATCTCGGCGTGCGCGGCGTGCA (as3), 
TCAACGAGGCCGGCCGCGGCTCGAAGGCCGTGTACAACTTCG (s4), 
CGGCCTGCGAGATCTTCAGCGACTCCGAGCCCAGCTTCTCGA (as4).  
3.2.2.3 Primers for PCR amplification of 87 bp ova fragment 
CACCCATATGATCTCGCAGGCCGTG (OTI-NdeI 5’, sense), 
GGTGGAATTCGCGGCCGGCCTCGTT (OTII-EcoRI 3’, antisense) 
3.2.2.4 PCR amplification for screening and sequencing 
Sense: CFP10-XbaI 5’ and Antisense: OTII-EcoRI 3’. High Pure PCR Product 
Purification Kit (Roche) was used, and the product sequenced by the University of Pittsburgh 
Sequencing Core facility (Pittsburgh, PA). 
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3.2.3 Mice and bacterial infections 
Six- to eight-week old C57BL/6 and B6.SJL-Ptprc
a
 Pepc
b
/BoyJ (CD45.1) mice were 
purchased from Jackson Laboratories (Bar Harbor, Maine), while OTI and OTII T cell receptor 
transgenic mice on a C57BL/6 RAG1-/- background (kindly provided by Louis D. Falo) were 
bred at the University of Pittsburgh Biotechnology Center (Pittsburgh, PA). Mice were kept 
under specific pathogen-free conditions in a BSL3 facility. OTI and OTII cells were purified 
from naïve spleens using MACS cell separation technology (Miltenyi, Auburn, CA), according 
to manufacturer’s protocol. 5*103 OTI and OTII cells in PBS (Sigma, St. Louis, MO) were 
adoptively transferred to WT C57BL/6 or CD45.1 mice. 24 hours later, the mice were infected 
with either WT M. tuberculosis or M. tuberculosis-ova, using a nose-only exposure aerosolizer 
(Intox, Moriarty, NM) [191]. This delivered approximately 10-20 colony forming units (CFU) 
per lung, estimated by plating of whole lung homogenate 24 hours post-infection on 7H10 media 
agar (Difco, Sparks, MD) and incubating at 37ºC, 5% CO2 for 3 weeks. Four to twelve mice 
were used per time-point per experimental procedure. Experiments were performed at least 
twice. Animal protocols were approved by the University of Pittsburgh Institutional Animal Care 
and Use Committee. 
3.2.4 Antibiotic treatment 
For secondary challenge experiments, infected mice were treated for three months with 
0.1g/L isoniazid (Sigma), 0.1g/L rifampin (rifampicin, Sigma) and 8g/L pyrazinamide (Acros, 
Geel, Belgium) in drinking water. Plating of whole lung homogenates confirmed that no bacteria 
could be cultured from the lungs after antibiotic treatment. 
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3.2.5 PD-1 signal blocking treatment 
Treatment was initiated during the chronic phase of infection (eight weeks post-infection) 
and was continued for four weeks. Mice were injected intraperitoneally twice a week with anti-
PD-1 (200µg, clone 29F.1A12) and anti-PD-L1 (200µg, clone 10F.9G2X) antibodies, or with 
PBS, as in [192]. The antibodies were kindly provided by Gordon J. Freeman. 
3.2.6 Harvesting of lungs and lymph nodes 
Organs were crushed through a 40μm cell strainer with a 5ml syringe plunger to obtain 
single-cell suspensions. An aliquot was used to determine bacterial load by plating serial 
dilutions on 7H10 media agar. For the remainder of the samples, red blood cells were lysed with 
an NH4Cl/Tris solution and washed in DMEM (Sigma). Cells were resuspended in T cell 
medium (DMEM supplemented with 10% FBS [Sigma], 1mM Na-pyruvate [Sigma], 2mM L-
glutamine [Invitrogen], 25mM HEPES [BioWhittaker, Walkersville, MD] and 50μM 2-ME 
[Sigma]) and counted based on trypan blue exclusion (Sigma). 
3.2.7 ELISpot assay 
Bone-marrow derived dendritic cells (DC) were used as antigen-presenting cells in 
ELISpot assays. Mouse bone-marrow was cultured for six days in DMEM media supplemented 
with 10% FBS, 2mM L-glutamine, 1000U/ml GM-CSF (kindly provided by Binfeng Lu) and 
20ng/ml IL-4 (PeproTech, Rocky Hill, NJ). Cells were split and media added on day three. DC 
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were either left uninfected or infected with M. tuberculosis at a multiplicity of infection of 3 for 
24 hours in media lacking IL-4. 
ELISpot plates (MultiScreen HTS 96-well, Millipore, Billerica, MA) were coated with 
anti-mouse IFN- antibody (10μg/ml, clone R4-6A2) in PBS. 5*104 cells were co-incubated for 
48 hours with 4*10
4
 DC. 4μg/ml peptide [GAP (GAPINSATAM) or ova (SIINFEKL)] 
(GenScript, Piscataway, NJ) was added to DC to stimulate antigen-specific responses, while M. 
tuberculosis-infected DC were used to stimulate total M. tuberculosis-specific responses. 
Uninfected DC and media were used to determine background levels of IFN- secretion. 
Biotinylated anti-mouse IFN- antibody (5μg/ml, clone XMG1.2), streptavidin-conjugated 
peroxidase (PK6100, Vector Laboratories, Burlingame, CA) and AEC substrate (PK4200, Vector 
Laboratories) were used to detect IFN-. Spots were counted on an ImmunoSpot automatic 
ELISpot reader (Cellular Technology, Shaker Heights, OH). 
3.2.8 Flow cytometry 
Cells were incubated with GAP (GAPINSATAM) or ova (SIINFEKL) tetramer-PE 
(Beckman Coulter, Fullerton, CA) for 30 min at 4ºC in T cell medium. The cells were then 
washed and incubated at 37ºC for 5 hours in T cell medium containing 3μM monensin (Sigma), 
anti-CD107a and CD107b FITC antibody, anti-CD28 antibody (clone 37.51, 1μg/ml) and anti-
CD3 antibody (clone 145-2C11, 0.1μg/ml). Cells were then washed and stained with anti-CD8 
PerCP antibody in 20% mouse serum (Gemini, West Sacramento, CA) in FACS buffer (PBS 
with 0.1% BSA [Sigma] and 0.1% NaN3 [Sigma]) for 15 minutes, washed and fixed in 2% 
paraformaldehyde (Sigma). Cells were permeabilized in permeabilization buffer (FACS buffer 
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containing 0.2% saponin [Calbiochem, Gibbstown, NJ]) and stained with anti-IFN--PE-Cy7, 
anti-granzyme B-APC (Invitrogen). Samples were read on a FACS Aria (BD Biosciences, San 
Jose, CA) and analyzed with FlowJo (TreeStar, Ashland, OR) software. Antibodies were 
obtained from BD Biosciences, unless otherwise stated. 
3.2.9 In vivo cytotoxicity assay 
Uninfected splenocytes were labeled with 0.4mM or 5mM CFSE (Molecular Probes, 
Eugene, OR) for 15 minutes at 37ºC. The reaction was quenched with T cell medium, and cells 
washed in 20% FBS in PBS. CFSE
low
 cells were pulsed for 1 hour with 20μg/ml peptide in PBS 
(GAP or ova for antigen-specific killing, LCMV gp33 to 41 for controls). 
CFSE
high
 and CFSE
low
 cells were mixed 1:1 and approximately 5*10
7
 cells injected into 
the tail veins (four mice/group/time-point). Mice were sacrificed 18 hours later and cell 
homogenates harvested from lungs and lymph nodes. Cells were washed in FACS buffer and 
fixed in 4% paraformaldehyde. Samples were read on a FACSCalibur (BD Biosciences) and 
analyzed with FlowJo software. Peptide-specific lysis was measured by loss of CFSE
low
 cells 
compared to CFSE
high
 cells (ratio averaged per group). 
%peptide-specific lysis= 100 – 100*[(%CFSElow/%CFSEhigh) from GAP or ova group / 
(%CFSE
low
/%CFSE
high
) from LCMV group]. 
3.2.10 Statistical analysis 
GraphPad Prism 4.01 (GraphPad Software, La Jolla, CA) was used for graphing and 
statistical analysis. Unpaired two-sided t tests were used for two-group analysis, while two-sided, 
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nonparametric Spearman rank correlation coefficient tests were used to determine correlation. P 
values of <0.05 (*) and 0.01 (**) were considered significant and highly significant, 
respectively. 
3.3 RESULTS 
3.3.1  Generation of M. tuberculosis-ova strain for analysis of the CD8 T cell 
response 
A scarcity of known M. tuberculosis-specific CD8 T cell immunodominant epitopes in 
C57BL/6 mice [193] led us to generate a recombinant M. tuberculosis (M. tuberculosis-ova) 
expressing ova epitopes fused to culture filtrate protein 10 (CFP10). CFP10 is a small protein 
that forms a heterodimer with early secreted antigenic target 6-kDa (ESAT-6), and together they 
are secreted by M. tuberculosis [194]. CFP10 epitopes are not efficiently presented by MHC 
class I molecules in C57BL/6 mice and thus do not induce CD8 T cell responses [186]. However, 
CFP10 elicits robust CD8 T cell responses in humans [195], non-human primate [196, 197] and 
the C3H mouse strain [186], indicating that CFP10 has access to the antigen presentation 
pathway. For this reason, CFP10 was chosen as a carrier protein for the ova epitopes. This 
construct enables us to take advantage of the numerous ova-specific immunologic reagents 
available, as well as to compare ova-specific responses in the context of M. tuberculosis 
infection to those in other infections where recombinant ova-expressing strains have been used. 
Here we used this construct to compare responses to two different CD8 T cell epitopes: ova and 
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an endogenous M. tuberculosis CD8 T cell epitope (GAPINSATAM, designated GAP, from 
Rv0125 [198]). 
Ova epitopes 257 to 264 (SIINFEKL) and 323 to 339 (ISQAVHAAHAEINEAGR) are 
recognized by H-2b restricted OTI transgenic CD8 T cells and I-Ab restricted OTII transgenic 
CD4 T cells, respectively [199], as well as non-transgenic T cells in C57BL/6 mice. M. 
tuberculosis-ova was generated by fusing OTI and OTII recognized sequences downstream of 
the intact CFP10 gene and upstream regulatory sequences. The CFP10-ova fusion gene was 
inserted into pMH94, a vector that integrates into the bacterial genome [188] (Figure 2A and B). 
Integration of the pMH94CFP10ova plasmid did not alter the growth rate or survival of the 
bacterium in vitro or in vivo, compared to the parent M. tuberculosis Erdman strain (data not 
shown). M. tuberculosis-ova, but not WT M. tuberculosis, induced ova-specific responses, as 
demonstrated by IFN- ELISpot assay (Figure 2C, P<0.01). Ova-specific CD4 T cell responses 
were always weaker than ova-specific CD8 T cell responses. Endogenous T cell responses to 
GAP (CD8) and ESAT-6 peptide amino acids 1 to 20 (CD4) were not altered by the plasmid 
integration, nor were any differences in survival of mice inoculated with M. tuberculosis-ova and 
WT M. tuberculosis observed. 
In summary, we generated a recombinant M. tuberculosis strain expressing ova epitopes, 
expanding the repertoire of peptides for detection of CD8 T cells during M. tuberculosis 
infection.  
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Figure 2 Generation and screening of M. tuberculosis-ova. 
A) Map of pMH94CFP10ova integration vector, drawn in Vector NTI suite 8 (InforMax Inc). 
CFP10 and the upstream sequence were inserted into pMH94, followed by the ova sequence. The 
plasmid lacks an origin of replication in M. tuberculosis, and is lost unless it is integrated in a 
site-specific manner into the genome by the integrase via the attP site. Recombinant colonies 
were selected based on kanamycin resistance (KanR). B) PCR screening for integration of 
pMH94CFP10ova into M. tuberculosis. Lane 1 shows a 100 bp DNA ladder (Invitrogen). Lanes 
2 (WT M. tuberculosis) and 4 (M. tuberculosis-ova) show positive controls, screening for 
endogenous copies of CFP10 (225 bp). Lanes 3 (WT M. tuberculosis) and 5 (M. tuberculosis-
ova) screen for pMH94CFP10ova with primers specific for the ends of the CFP10-ova fusion 
gene (312 bp, indicated by the arrow). The figure has been edited to remove irrelevant lanes. C) 
ELISpot assay measuring IFN- secretion in response to M. tuberculosis, endogenous T cell 
epitopes (GAP and ESAT-6), ova CD8 T cell epitope and background levels (media). The data 
are the means ± standard errors of mean (SEM) of four mice. Ova-specific CD8 T cell responses 
induced by M. tuberculosis-ova were statistically different (**, P<0.01) from responses induced 
by WT M. tuberculosis, while other responses were not statistically different.  
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3.3.2 Expansion of CD8 T cells specific for GAP and ova during primary infection with 
M. tuberculosis-ova 
In C57BL/6 mice infected by aerosol with a low dose of M. tuberculosis, primary T cell 
responses can be detected two to three weeks post-infection. We used MHC class I tetramers to 
quantify GAP- and ova-specific populations of CD8 T cells. In infected mice, GAP- and ova-
specific CD8 T cells comprised about 2 to 10% of the primary CD8 T cell response in the lungs 
and 1 to 13% in the lymph nodes (Supplementary Figure 1A and B). This response was sustained 
for at least seven months post-infection. GAP- and ova-specific CD8 T cell responses were 
similar, peaking first at three weeks post-infection and then contracting as bacterial expansion 
was controlled (Figure 3A to C, [200]). GAP- and ova-specific CD8 T cells expanded again late 
in infection in the lung, which was associated with an increase in bacterial load (Figure 3C, 
P<0.05, week sixteen versus twenty-eight post-infection). CD8 T cell expansion late in infection 
was observed previously [200]. 
In summary, GAP and ova induced similar primary CD8 T cell expansion, which were 
detected in both acute and chronic phases of infection in the lung and, to a lesser extent, in the 
mediastinal lymph node.  
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Figure 3 M. tuberculosis-ova induces similar GAP- and ova-specific responses. 
Based on percent tetramer positive CD8 T cells (Supplemental Figure 1A and B) and live cell 
numbers (data not shown), the number of tetramer positive cells in A) lungs and B) lymph nodes 
were calculated. The frequency of tetramer-specific cells during primary (1’) and secondary (2’) 
infections was significantly different 0, 2, 3 and 4 weeks post-infection for ova-specific cells (o*) 
and 0, 2 and 4 weeks post-infection for GAP-specific cells (g*). The frequency of ova and GAP-
specific cells was significantly different at eight weeks (lung) and twenty-eight weeks (lymph 
node) post-primary infection (go1*) and four weeks (lung) post-secondary infection (go2*). C) 
Bacterial load in lungs. Primary and secondary infections were statistically different at three and 
four weeks post-infection (P<0.01). Data are mean ± SEM of four (A and B) to twelve (C) mice 
per time-point.  
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3.3.3 GAP- and ova-specific CD8 T cell function during primary infection 
To characterize the effector functions of individual M. tuberculosis-specific CD8 T cells 
over the course of infection, we examined CD8 T cell mediated cytotoxicity and cytokine 
production on a single cell basis using flow cytometry. For this, we used intracellular cytokine 
staining for IFN- and surface staining for CD107 (Supplemental Figure 2A). CD107a and 
CD107b are lysosomal proteins that are transiently exposed to the surface upon degranulation, 
which is indicative of cytotoxicity [201]. Incubation of the cells with anti-CD107 antibody 
during stimulation provides an assay to assess which cells degranulated during the incubation 
period. 
Two weeks post-infection GAP- and ova-specific CD8 T cells started expanding in the 
lymph nodes (Figure 3B); by three weeks post-infection primed GAP- and ova-specific CD8 T 
cells had expanded and migrated to the lungs (Figure 3A). By three weeks post-infection 25% of 
GAP- and ova-specific CD8 T cells in lungs had acquired the ability to be cytotoxic (i.e. 
CD107+), while little degranulation was detected in the lymph nodes (Supplemental Figures 3A 
to B and 4A and B). Approximately 15% of GAP- and ova-specific CD8 T cells in both lungs 
and lymph nodes acquired the ability to secrete IFN-. Less than 5% of the cells were able to 
both degranulate and secrete IFN-, indicating that distinct populations of cells carry out these 
functions. 
By four weeks post-infection there was an increase in the frequency and number of 
cytotoxic cells in the lungs, while there were fewer IFN- secreting cells (Figure 4A and B). 
However, IFN- production peaked at four weeks post-infection as measured by ELISpot assay 
using M. tuberculosis-infected DC (Supplemental Figure 5) or peptide pulsed DC as stimulators 
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(Figure 5A). The difference in results is likely due to the differences in the methods: ELISpot 
assay includes stimulation by antigen-pulsed or infected DC for two days, while intracellular 
cytokine staining occurs during a short (5 hour) stimulation with tetramer and anti-CD3/CD28 
antibody. The longer stimulation may induce production of IFN- from cells that are not 
immediately ready to produce it. There may also be differences in the sensitivity of the assays 
[202]. 
In vivo cytotoxicity assays (Figure 5B) showed a peak in cytotoxic activity against GAP- 
and ova peptide-loaded cells in the lungs at four weeks post-infection. Cytotoxicity decreased 
after the four-week peak, but then slowly increased during the chronic phase of infection. 
Comparison of the pattern of GAP-specific cytotoxicity and the frequency of CD107+ GAP-
specific cells in lungs over the course of infection (Figure 5C) indicates that CD107 surface 
expression is a good indicator of cytotoxicity during primary M. tuberculosis infection.  
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Figure 4 IFN- secretion and degranulation are carried out by distinct populations of cells 
in lungs. 
Based on GAP and ova-specific CD8 T cell numbers from Figure 3A and percent IFN-+ and 
CD107+ cells (Supplemental Figure 3A and B), numbers of cells per organ were calculated. A) 
and B) are primary infection, C) and D) are secondary infection. A) and C) are GAP, B) and D) 
are ova. The data are mean ± SEM of four mice per time-point. There was a significant 
difference in the frequency (P<0.05) and number (P<0.05) of IFN-+CD107+ cells between 
primary and secondary infections for GAP-specific cells at two weeks post-infection and ova-
specific CD8 T cells at two and four weeks post-infection.  
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Figure 5 Functional assays for GAP- and ova-specific cytotoxicity and IFN- secretion. 
A) ELISpot assay, where lung cells were incubated with DC pulsed with GAP or ova peptide 
(SIINFEKL) for 48 hours. There was no background level of IFN- secretion, measured by 
incubating cells with either T cell media or unpulsed, uninfected DC (data not shown). Data are 
mean ± SEM of four mice per time-point. There was no statistical significance between primary 
and secondary infections, except for ova-specific cells at eight weeks post-infection (P<0.05). B) 
In vivo cytotoxicity assay in lung. Data are the average of four mice per group. C) GAP-specific 
cytotoxicity versus the frequency of CD107+ GAP-specific CD8 T cells in lung. There was a 
significant correlation (P<0.05) between cytotoxicity and CD107 surface expression during 
primary infection, as measured by the Spearman non-parametric test, while there was no 
significant correlation during secondary infection.  
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By seven months post-infection, expansion of CD107+ and IFN-+CD107+ T cells was 
observed (Figure 4A and B, Supplemental Figure 3A and B, Supplemental Figure 5A and B). 
These data indicate a dynamic response to M. tuberculosis over the acute and chronic phases of 
infection, with changes in the effector functions of CD8 T cells. However, the assays are not able 
to discriminate whether cellular function changes over time or whether new cells appear with 
different functions. 
In summary, cells primed in the lymph nodes primarily secreted IFN-, but lost the ability 
to secrete IFN- after the first month of infection and later acquired cytotoxic function. Effector 
cells migrating to the lungs retained the phenotype expressed in lymph node, or acquired 
cytotoxic function. Again, IFN- was mostly lost after the first month of infection. Finally, 
cytotoxicity and secretion of IFN- were carried out by distinct cell populations. 
3.3.4 Blocking PD-1 signaling during primary infection 
PD-1 is a negative costimulatory molecule, whose expression is upregulated following T 
cell activation [192]. High expression level of PD-1 has been implicated in CD8 T cell 
exhaustion in several chronic infections in humans, e.g. HIV [203, 204] and HCV [205], as well 
as in animal models, e.g. LCMV [192]. Using congenic strain markers, we examined temporal 
expression of PD-1 by CD45.2+ OTI T cells adoptively transferred into CD45.1+ mice. The 
frequency of M. tuberculosis-specific cells expressing PD-1 increased in both lungs and lymph 
nodes following infection, and continued to increase as infection progressed (Figure 6A). 
Geometric mean fluorescence intensity (MFI), however, was highest immediately upon priming, 
after which PD-1 levels remained low (Figure 6B, Supplemental Figure 2G and H). 
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Administration of PD-1 blocking antibody during chronic infections [192, 203, 206, 207] 
has been shown to improve CD8 T cell function and lower viral loads. Thus, we examined 
whether intraperitoneal administration of blocking antibodies against PD-1 and PD-L1 would 
significantly alter CD8 T cell function, specifically the ability of CD8 T cells to make IFN- and 
be cytotoxic. Treatment was initiated eight weeks post-infection, which we define as the 
beginning of chronic phase, and was continued over a four week period. This treatment did not 
produce cells capable of being both cytotoxic and secreting IFN- (Figure 6C, Supplemental 
Figure 2D), indicating that PD-1 is not involved in maintaining the functional distinction of 
cytotoxic cells and cells that secrete IFN-. Treatment did not significantly alter the frequency of 
CD107+ and IFN-+ nor bacterial load (Figure 6D). 
In summary, while the frequency of PD-1 expressing cells increased with time, 
expression levels on a per-cell basis decreased, indicating that newly primed cells expressed PD-
1 and that its expression then decreased. Blocking PD-1 signaling had no appreciable effect on 
CD8 T cell function as measured here. It is possible that blocking PD1 signaling at a different 
time point, either earlier or later in infection, may affect CD8 T cell function.  
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Figure 6 Blocking PD-1 signal in vivo does not generate IFN-+CD107+ cells. 
5*10
3
 OTI cells (CD45.2) were adoptively transferred to CD45.1 mice, which were subsequently 
infected with M. tuberculosis-ova. Using anti-CD45.2 antibodies, responses of these cells were 
examined over the course of infection. A) Percent CD45.2+ OTI+ cells expressing PD-1, B) 
geometric mean fluorescence intensity (MFI) of PD-1 staining in A). (C and D) Mice treated 
with anti-PD-1 and anti-PD-L1 antibodies, or with PBS, for four weeks. Ab, antibody; a-, anti-. 
C) GAP+ CD8 T cells expressing IFN- and surface CD107. D) Bacterial load in lungs and 
lymph nodes. Data are mean ± SEM for three or four mice per experimental group. 
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3.3.5 Expansion of CD8 T cells specific for GAP and ova epitopes during rechallenge with 
M. tuberculosis-ova 
As a model for studying memory T cell responses, mice were infected with M. 
tuberculosis for two months and then treated with antibiotics in drinking water for three months, 
after which no bacteria could be cultured from whole lung homogenates. Mice were then re-
infected and sacrificed at weekly time-points. Recalled memory T cells can be examined for the 
first two weeks post-infection. After that time the response is likely to consist of both memory 
and primary T cells, since bacteria are not cleared, allowing for priming of new T cells. 
GAP- and ova-specific memory CD8 T cell expansion was significantly larger in terms of 
number of cells than primary CD8 T cell expansion to these epitopes (Figure 3A and B, P<0.01), 
and they represented a greater proportion of the total CD8 T cell response (Supplemental Figure 
1, P<0.01 for ova, P<0.05 for GAP). This indicates that GAP and ova CD8 T cell epitopes are 
presented during both primary and secondary infections. Memory T cell expansion against M. 
tuberculosis was associated with an earlier control of bacterial numbers in the lung (Figure 3C, 
P<0.01). This protection was transient, as previously published [208], indicating that memory 
CD8 T cells induced by infection in this model do not confer significant long-term protection 
against subsequent M. tuberculosis infection. M. tuberculosis-specific CD8 T cells did not 
contract despite control of bacterial infection, reaching higher numbers in the lungs than during 
primary infection (Figure 3A). Masopust et al. showed, using heterologous infections, that cells 
contracted more slowly with each subsequent infection [209]. Based on this, chronic antigen 
exposure during M. tuberculosis infection may cause the slow contraction of T cells.  
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In summary, both GAP and ova memory CD8 T cells are present in the lungs at higher 
levels during M. tuberculosis re-infection, indicating a more rapid and robust response to 
secondary challenge. 
3.3.6 Function of CD8 T cells specific for GAP and ova during rechallenge with M. 
tuberculosis-ova 
Before re-infection of mice, residual M. tuberculosis-specific CD8 T cells in the lungs 
had a cytotoxic phenotype (CD107+) (Figure 4C and D, Supplemental Figure 3C and D, 
Supplemental Figure 5C and D). There was a continued expansion of CD107+ cells in the lungs 
following re-infection. IFN- secreting cells appeared by two weeks post-infection, measured by 
ELISpot (Figure 5A). As in primary infection, almost no cells were observed that both secreted 
IFN- and degranulated (Figure 4C and D, Supplemental Figure 3C and D, Supplemental Figure 
5C and D). By three weeks post-infection, CD8 T cells expressing IFN- were observed by flow 
cytometry. These cells are presumably newly primed, since they correspond to the peak of these 
cells in primary infection. After three weeks post-infection cytotoxicity, as measured by the in 
vivo cytotoxicity assay, decreased (Figure 5B) despite continued expansion of CD107+ cells 
(Figure 4C and D). The lack of correlation between GAP-specific cytotoxicity and the frequency 
of CD107+ GAP-specific cells in lungs (Figure 5C) suggests that although memory CD8 T cells 
are capable of degranulation, they are less efficient at killing targets during secondary infection. 
To summarize, cytotoxicity is the main function of M. tuberculosis-specific memory CD8 
T cells in the lungs, as appears to be the main function of primary CD8 T cell responses. By four 
weeks post-infection, however, the memory CD8 T cell response was altered compared to 
primary responses in that cytotoxicity had decreased. 
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3.3.7 Cytotoxic effector molecules 
To address a potential cause of decreased cytotoxicity during secondary infection, we 
examined expression of perforin and granzyme B (Supplemental Figure 2I). They are the 
primary cytotoxic effector molecules, stored in lytic vesicles, during M. tuberculosis infection 
[210]. While granzyme B protein levels were low in both primary and memory GAP-specific 
CD8 T cells in unstimulated samples (Figure 7A), incubation with anti-CD3 and anti-CD28 
antibodies could increase expression in both primary and memory cells (Figure 7B, P<0.05 at 
weeks two and six post-infection). Perforin levels, on the other hand, were high in both primary 
and secondary unstimulated GAP-specific CD8 T cells (Figure 7A). 
Both primary and memory GAP-specific CD8 T cells had high levels of perforin, while 
granzyme B could be induced in both. Thus, a lack of effector molecules in recalled CD8 T cells 
is unlikely to account for the reduction in actual cytotoxicity during the later memory response.  
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Figure 7 CD8 T cells express perforin, while granzyme B expression can be induced. 
 A) Cells were stained, without incubation, for perforin (FITC, clone dG9) and granzyme B 
(GrB), using fixative and protocol from Apo-Active 3 (Cell Technology, Mountain View, CA). 
B) Cells were stained for granzyme B after a 5 hour incubation, as described in Materials and 
Methods. Data are mean ± SEM of three or four mice per experimental group.  
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3.3.8 Degranulation and IFN- secretion are highest in IFN-+CD107+ cells 
Although IFN-+CD107+ cells were a very small population during primary infection, 
these cells produced the most IFN- (Figure 8A, IFN-+CD107+ versus IFN-+CD107- cells at 
four weeks post-infection, P<0.05). The quantity of IFN- secreted on a per-cell basis decreased 
during secondary infection (Supplemental Figure 2B and C, Figure 8A IFN-+CD107+ cells at 
four weeks post-infection. 1’ versus 2’ responses, P<0.05), while the frequency of secreting cells 
was slightly increased (Figure 4A and B, four weeks post-infection. 1’ versus 2’ responses, 
P<0.05).  
During primary infection, CD107 MFI remained constant and there was little difference 
between CD107+ and IFN-+CD107+ cells until late in infection, when there was increased 
degranulation, especially by IFN-+CD107+ cells (Figure 8B). Both numbers (Figure 4A and B, 
four weeks post-infection. 1’ versus 2’ responses, P<0.01) and MFI (Supplemental Figure 2E 
and F, Figure 8B, P<0.01) of degranulating cells were higher during secondary infection, while 
actual in vivo cytotoxicity was decreased compared to primary infection (Figure 5B and C). 
In summary, IFN-+CD107+ cells may be the best effector cells because of their 
increased secretion of IFN-. However, they constituted a small population and their contribution 
to control of M. tuberculosis thus small, while less efficient cells constituted the bulk of the 
response.  
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Figure 8 IFN-+CD107+ cells secrete more IFN- and degranulate more than cells limited 
to either function. 
The geometric MFIs of CD107+ and IFN-+ GAP-specific cells was analyzed. A) IFN- MFI, B) 
CD107 MFI of cells that both secrete IFN- and degranulate or are limited to either function. 
Data are mean ± SEM of four mice per time-point. There were significant differences in both 
IFN- secretion and degranulation between primary and secondary infections (P<0.05) at three 
and four weeks post-infection. IFN-+CD107+ cells expressed significantly more IFN- four 
weeks post-infection than IFN-+CD107- cells (P<0.01) while there was no significant 
difference in degranulation between IFN-+CD107+ and IFN--CD107+ cells.  
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3.4 DISCUSSION 
 In this study, we characterized the multifunctional nature of M. tuberculosis-specific CD8 
T cell responses in the murine model. Using a recombinant strain expressing ova epitopes (M. 
tuberculosis-ova), ova-specific CD8 T cell responses were shown to be comparable to CD8 T 
cell responses to an endogenous M. tuberculosis epitope (GAP) over the course of both primary 
and secondary infections in C57BL/6 mice. M. tuberculosis-ova persistence in the host is 
comparable to that of the WT strain, despite the addition of a CD8 T cell epitope to CFP10. The 
GAP- and ova-specific CD8 T cell responses are comparable to, albeit weaker, than those seen 
against M. tuberculosis-specific CD8 T cell epitopes such as TB10.3/4 [184, 185]. There has 
been a lack of good reagents to study CD8 T cell responses in C57BL/6 mice, even though it is 
the most commonly used mouse strain in TB research. Advances in the use of tetramers and new 
assays for function of CD8 T cells, as well as the use of the recombinant M. tuberculosis-ova 
strain and ova-specific reagents, will allow for more in-depth studies of CD8 T cell responses in 
TB. 
 IFN- secretion and cytotoxic function have been traditional measurements of CD8 T cell 
responses. Study of CD8 T cell responses to M. tuberculosis infection has been complicated by 
the fact that CD8 T cells are a minor contributor of IFN-, compared to CD4 T cells ([211]; our 
unpublished results) and until recently, in vitro expansion of M. tuberculosis-specific CD8 T 
cells was required to measure cytotoxic function [200]. In other systems, it has been reported that 
induction of IFN- secretion requires more antigen than cytotoxicity [212]. While M. 
tuberculosis expansion is contained by four weeks post-infection, we previously showed that 
antigen accumulates in the lungs as the infection progresses [200]. This indicates that the lack of 
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antigen exposure is likely not the cause of the low number of IFN- secreting CD8 T cells. This 
is supported by the finding that co-incubation in an ELISpot assay with antigen-pulsed DC was 
not sufficient to induce IFN- secretion from CD8 T cells after the peak of infection at four 
weeks (Figure 5A). It is possible that IFN- secreting cells contracted, leaving cells primed for 
other functions, that cells with different functions entered the lungs, or that IFN- secretion was 
blocked. This block may be relieved as bacterial infection is cleared by antibiotics, as memory 
cells could respond by making IFN-, although the per-cell amount was reduced compared to 
that produced during primary infection (Figure 8A). 
 Studies examining CD8 T cell mediated cytotoxicity in TB have generated conflicting 
results. Previous work from our laboratory, using an in vitro cultured cells from C57BL/6 mice 
to assay for cytotoxicity, indicated that CD8 T cells lost cytotoxic function by four weeks post-
infection [200]. Work by Kamath et al., using in vivo cytotoxicity assay in BALB/c mice, 
indicates that CD8 T cells retain their cytotoxic function throughout the infection [186]. It is 
likely that in vitro culture of cells led us to underestimate the frequency of cytotoxic CD8 T cells 
in infected lungs, as cells from the lungs can be highly activated [213] and prone to apoptosis in 
vitro. Recent work by Billeskov et al. [184], using the in vivo cytotoxicity assay in C57BL/6 
mice, indicated that cytotoxicity peaks at four weeks post-infection and decreases slightly with 
time. We observed decreased cytotoxicity after four weeks, tracking a different CD8 T cell 
population, followed by an increase late in primary infection as the frequency of degranulating 
cells increased. The frequency of cells expressing surface CD107 correlated well with 
cytotoxicity during primary infection but not during secondary infection, where cytotoxicity was 
decreased compared to that seen during primary infection despite an increase in the frequency of 
degranulating cells. Wolint et al. [214] showed that cytotoxicity by memory cells was related to 
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effector molecules in lytic granules rather than degranulation. Partial CD8 T cell exhaustion 
caused by a lack of effector molecules may be the cause of decreased cytotoxicity during 
secondary M. tuberculosis infection, although the cells expressed perforin, and granzyme B 
expression could be induced by antigen stimulation. It is possible that antigen-pulsed targets used 
for in vivo cytotoxicity assays did not stimulate the cells sufficiently to induce granzyme B 
expression.  
 An unexpected finding was that, on a single cell basis, the vast majority of CD8 T cells 
induced by infection with M. tuberculosis were not capable of both secreting IFN- and 
degranulating. This contrasts with data from other chronic infections, such as HIV-1, where CD8 
T cells chronically exposed to antigen are able to perform both functions [215]. During chronic 
LCMV infection, cells appear to be primarily cytotoxic while CD8 T cells from acutely infected 
mice retain the ability to be both cytotoxic and secrete IFN- [216]. Presumably, the phenotype 
of cytotoxicity only is due to constant antigen exposure during chronic LCMV infection, leading 
to exhaustion of the CD8 T cells. However, it is unlikely that distinct CD107+ and IFN-+ cell 
populations that arise during the initial phase of M. tuberculosis infection are due to exhaustion 
from chronic antigen exposure, as the inoculum is low and the bacterium slow growing, while 
the functional division, i.e. IFN- secretion or degranulation, is maintained from the initial 
priming events of the adaptive immune response. Additionally, while the frequency of cells 
expressing PD-1 increased over the course of M. tuberculosis infection, which has been 
correlated to CD8 T cell exhaustion in other infections [192, 204], the expression levels 
decreased following priming, and administration of blocking antibodies for four weeks had no 
significant effect on CD8 T cell function or the bacterial load (Figure 6). 
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 In summary, M. tuberculosis infection yielded CD8 T cells that were to a large extent 
unable to both be cytotoxic and secrete IFN- and memory responses that were less functional 
than primary responses. Elucidating the cause of the poor quality of CD8 T cell responses may 
enable generation of improved vaccines against M. tuberculosis. 
 74 
4.0  MEMORY CELLS INFLUENCE THE NUMBER AND QUALITY OF NEW CD8 
T CELLS DURING M. TUBERCULOSIS INFECTION 
4.1 INTRODUCTION 
As discussed in chapter 3, primary adaptive immune responses are induced 
approximately two weeks post-infection in the murine model. Bacterial expansion is contained 
around four weeks post-infection, after which the bacterial load remains steady. Memory cells 
respond faster and contain the bacterial expansion at approximately two weeks post-infection 
[103, 217] but are neither able to prevent infection nor prevent disease. The same holds true for 
humans who have been previously vaccinated with BCG or infected with M. tuberculosis as 
these people can still be infected with M. tuberculosis and develop disease, despite the presence 
of memory cells [218, 219] (Figure 1G). We showed in chapter 3 that M. tuberculosis-specific 
memory CD8 T cells are less functional than primary CD8 T cells in that they secrete less IFN- 
and are less cytotoxic in mice [103]. This finding underscores the importance of primary CD8 T 
cell responses. 
Both viral and bacterial infection models have shown that pre-existing memory cells can 
influence new CD8 T cell responses [220-225]. Primary and memory cells can respond during 
Listeria monocytogenes [220, 222, 224, 225] and lymphocytic choriomeningitis virus (LCMV) 
[222, 223] infections. However, the larger the memory response, the smaller the primary 
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response and priming of new CD8 T cell responses is dependent on the dose of infection [225]. 
On the other hand, memory cells can enhance the quantity and quality of new CD8 T cell 
responses through improved CD4 T cell help [224]. 
Due to the extent of BCG vaccination and M. tuberculosis infection in the human 
population, there is a very large pool of people who have formed memory responses to the 
bacteria, which can influence immune responses upon further infection or vaccination. In this 
study, we examined whether pre-existing memory influences the quality and quantity of new 
CD8 T cell responses. Our experimental system (described below) does not require adoptive 
transfer of cells. This limits cell manipulation and ensures that CD8 T cell responses were 
induced from a physiologically relevant number of progenitor cells that are in their natural niche. 
 Our findings indicate that a sufficiently high bacterial inoculum was required for primary 
CD8 T cell responses to be induced in the lungs when there was pre-existing memory. This did 
not hold true for the lymph nodes, where a lower bacterial load could prime larger CD8 T cell 
responses. Memory responses could affect the quality of the new CD8 T cell responses. CD8 T 
cells producing IFN- were more multifunctional when they were primed in the presence of 
memory cells, and they secreted significantly more IL-2 than CD8 T cells primed in naive mice. 
Taken together, these results indicate that there is significant interaction between memory 
cells and newly primed CD8 T cells, which can influence both the quality and quantity of the 
new CD8 T cell responses. 
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4.2 MATERIALS AND METHODS 
4.2.1 Mice 
C57BL/6 mice (six to eight week old) were obtained from Jackson Laboratories and kept 
in a BSL3 facility under
 
specific pathogen-free conditions. Three to four mice were used per 
time-point. The University
 
of Pittsburgh Institutional Animal Care and Use Committee approved 
all animal protocols used in this study.
 
4.2.2 Bacterial infections 
Mice were infected using a nose-only exposure aerosolizer (Intox) with either WT M. 
tuberculosis Erdman strain or M. tuberculosis-ova [103], a recombinant M. tuberculosis Erdman 
strain expressing CD4 and CD8 ovalbumin epitopes. Depending on the concentration of the 
bacterial inoculum, infection delivered approximately 2-150 CFU per lung, determined
 
by 
plating whole-lung homogenates at 24 h post-infection on 7H10
 
medium agar (Difco) and 
incubation at 37°C in
 
5% CO2 for three weeks. 
4.2.3 Viral infections 
The replication deficient Adenovirus-ova
 
vector was produced and provided by the 
University of Pittsburgh Vector Core Facility. Mice were infected intratracheally with 5*10
10
 
particles, based on a dose escalation study for induction of responses. 
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4.2.4 Antibiotic treatment 
For secondary challenge experiments, M. tuberculosis infected mice were treated with 0.1 
g/liter isoniazid (Sigma), 0.1 g/liter
 
rifampin (rifampicin, Sigma), and 8 g/liter pyrazinamide 
(Acros) in drinking water for three months. In our experience this treatment clears the infection, 
as no bacteria could be cultured from the lungs, determined by plating of whole-lung 
homogenates. Treatment was initiated early (two weeks) or late (two months) after infection to 
model acute and chronic infections, respectively. 
4.2.5 Harvesting of lungs and lymph nodes 
Single-cell homogenates were obtained by crushing lungs and lymph nodes through a 40-
µm cell strainer with
 
a 5-ml syringe plunger. An
 
aliquot was plated on 7H10 medium agar to 
determine the bacterial load. Red blood cells were lysed with an NH4Cl-Tris solution
 
and washed 
in DMEM (Sigma), after which cells were resuspended in T cell medium and counted
 
based on 
trypan blue exclusion (Sigma). 
4.2.6 Flow cytometry 
Cells were incubated with GAP-phycoerythrin (GAPINSATAM) and ova-
allophycocyanin (SIINFEKL) tetramers ([103], Beckman Coulter) for
 
30 min at 4°C in T cell 
medium, after which the cells were washed
 
and resuspended in T cell medium containing 3 µM 
monensin (Sigma), anti-CD107a and anti-CD107b fluorescein
 
isothiocyanate antibody, anti-
CD28 antibody (clone 37.51, 1
 
µg/ml), and anti-CD3 antibody (clone 145-2C11, 0.1 µg/ml). 
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Cells were incubated at 37°C for 5 h, then washed and stained for 15 min with anti-CD8-pacific 
blue and anti-CD4-alexa fluor 700 antibodies in 20% mouse serum (Gemini) in FACS buffer. 
Cells were washed and fixed in 2% paraformaldehyde (Sigma). 
Cells were permeabilized in permeabilization buffer, after which cells were stained with 
anti-IFN--phycoerythrin-Cy7, anti-IL-2 Peridinin Chlorophyll Protein Complex (eBioscience, 
San Diego, CA) and anti-TNF-biotin, followed by streptavidin-allophycocyanin-Cy7 antibody. 
Samples were
 
read on an LSR II (BD Biosciences) and data analyzed
 
with FlowJo software (Tree 
Star). Unless otherwise stated, all antibodies were
 
obtained from BD Biosciences. 
4.2.7 Statistical analysis 
Graphing and statistical analysis were performed using GraphPad Prism 4.01 (GraphPad 
Software). For two-group analysis, unpaired, two-sided t
 
tests were used. P values of <0.05 (*), 
<0.01 (**) and <0.001 (***) were considered significant, very  significant and highly significant, 
respectively. Spearman's rank correlation was used to determine correlation between bacterial 
load and the frequency of cells. P values of <0.05 and r
2
 coefficients approaching 0.5 were 
considered significant. 
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4.3 RESULTS 
4.3.1 Induction of ova-specific CD8 T cells in the presence and absence of pre-existing 
memory cells 
To study primary CD8 T cell responses induced in the presence of memory cells, we 
infected mice with WT M. tuberculosis, which induces GAP-specific CD8 T cell responses 
[103]. The mice were then treated with antibiotics to clear the infection and re-infected with M. 
tuberculosis-ova, a recombinant M. tuberculosis that induces ova-specific CD8 T cell responses 
in addition to GAP-specific responses [103]. Using tetramers, GAP-specific memory responses 
and ova-specific primary responses could be simultaneously examined (Figure 9A). For 
comparison, we also infected mice with M. tuberculosis-ova (Figure 9B) and examined ova-
specific primary responses that developed in the absence of memory cells. 
   
Figure 9 Experimental design to examine primary ova-specific responses induced in the 
presence or absence of memory cells. 
A) To examine ova-specific responses that develop in the presence of memory, mice were 
infected with WT M. tuberculosis, which induces primary GAP-specific responses. The mice 
were then treated with antibiotics for three months to clear the infection, after which the mice 
were infected with M. tuberculosis-ova, which induces responses to both GAP (memory 
response) and ova (primary response). B) To examine ova-specific responses that develop in the 
absence of memory, mice were infected with M. tuberculosis-ova, which induces primary 
responses to both GAP and ova.  
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The M. tuberculosis infection inoculum determines at what level the bacterial load 
reaches a plateau in murine lungs [226]. To examine the relationship between bacterial load and 
induction of CD8 T cells, we infected mice with a range of M. tuberculosis-ova inocula. During 
primary infection, there was not always a direct correlation between CD8 T cell numbers (termed 
"Primary cells") and bacterial load (Figure 10A to D). In most experiments, higher bacterial load 
induced larger CD8 T cell responses in the lung (Figure 10A and B, red squares). Low bacterial 
burden could, however, induce larger responses in both lung (data not shown) and lymph node 
(Figure 10C and D, blue squares), although this was not statistically significant. It is unknown 
what factors, besides bacterial load, determine the magnitude of the CD8 T cell responses. 
When data were pooled from eight independent experiments (Figure 11A to C) with a 
range of inocula (2-150 CFU, a physiologically relevant range of infection), the correlation (r
2
) 
between bacterial load in the lungs and the number of M. tuberculosis-specific CD8 T cells was 
weak. There was no significant correlation between bacterial load and CD8 T cell numbers in the 
lymph nodes (data not shown).  
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Figure 10 Bacterial load and induction of ova-specific CD8 T cells during primary 
infection. 
(A and C) Bacterial load during primary infection in the lungs (A) and lymph nodes (C). (B and 
D) Number of ova-specific CD8 T cells in the lungs (B) and lymph nodes (D), calculated by 
multiplying ova-tetramer positive cells by the frequency of live cells (data not shown). The mice 
received a high (130 CFU, red squares), medium (30 CFU, green squares) or low (2 CFU, blue 
squares) inoculum, determined by plating of lung homogenates 24 hours after infection. The high 
group had significantly higher bacterial burdens than the low group in lungs (P<0.05 at two 
weeks post-infection, P<0.02 at four and six weeks post-infection). There were significantly 
more ova-specific CD8 T cells in lungs of the high group than in the low group in lungs 
(P<0.005 at four weeks post-infection, P<0.05 at six weeks post-infection). Data are the means ± 
standard errors of the means from test results for three mice per time-point.  
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Figure 11 Correlation between bacterial load and induction of CD8 T cell responses in the 
lungs. 
Data was pooled from eight experiments where mice received infection inocula ranging from 2-
150 CFU. A) to C) are primary CD8 T cell responses, induced during a primary infection. D) to 
F) are secondary CD8 T cell responses, induced during a secondary infection. G) to I) are 
primary CD8 T cell responses, induced during a secondary infection. A), D) and G) are two 
weeks post-infection, B), E) and H) are four weeks post-infection and C), F) and I) are six weeks 
post-infection.  
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During secondary infection, there was no significant correlation between memory recall 
(termed "Memory cells") and bacterial load in the lungs (Figure 11D to F) or lymph nodes (data 
not shown). There was, however, a correlation between bacterial load and the number of ova-
specific CD8 T cells (primary CD8 T cell response induced in the presence of memory cells) in 
the lung (Figure 12A to B, red squares). The higher the bacterial load, the larger the ova-specific 
CD8 T cell response was in the lung. This did not hold true for the lymph node (Figure 12C to 
D), where lower bacterial load could prime larger ova-specific CD8 T cell responses (blue 
squares). The mice with the lowest bacterial burden (Figure 12, blue squares) induced ova-
specific CD8 T cells in the lymph nodes, but not in the lungs. GAP-specific recall was normal in 
these mice (Figure 12B and D, purple diamonds). This indicates that a sufficient bacterial load is 
required to induce new CD8 T cell responses in the lungs. When data were pooled, the 
correlation between the number of ova-specific CD8 T cells primed in the presence of memory 
and bacterial load was strong after two weeks post-infection in the lungs (Figure 11G to I) but 
not in the lymph nodes (data not shown). 
In summary, while lower bacterial load in the lymph nodes can result in priming of larger 
CD8 T cell responses, a sufficiently high bacterial burden is required to detect new CD8 T cell 
responses in the lungs when there is pre-existing memory. Induction of CD8 T cell responses in 
the absence of pre-existing memory and the recall of memory cells appear to be less dependent 
on bacterial burden.  
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Figure 12 Bacterial load and induction of ova-specific CD8 T cells during secondary 
infection. 
(A and C) Bacterial load during secondary infection in the lungs (A) and lymph nodes (C). (B 
and D) Number of ova-specific CD8 T cells in the lungs (B) and lymph nodes (D), calculated by 
multiplying ova-tetramer positive cells by the frequency of live cells (data not shown). The mice 
received a high (130 CFU, red squares), medium (30 CFU, green squares) or low (2 CFU, blue 
squares) inoculum, determined by plating of lung homogenates 24 hours after infection. The high 
group had significantly higher bacterial burdens than the low group in lungs (P<0.005 at week 
two post-infection and P<0.001 at four and six weeks post-infection) and lymph nodes (P<0.05 
at week two post-infection and P<0.002 at six weeks post-infection). There were significantly 
more ova-specific CD8 T cells in the high group than in the low group in lungs (P<0.0001 at four 
and six weeks post-infection). Data are the means ± standard errors of the means from test results 
for three mice per time-point.  
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4.3.2 Effect of bacterial load on the function of CD8 T cells 
To examine whether the bacterial burden had a signficant effect on the function of the 
cells, we examined the correlation between bacterial load and secretion of cytokines (IFN-, TNF 
and IL-2) or degranulation of CD8 T cells. To do this, we pooled data from the experiments 
above to get a range of bacterial loads (2-150 CFU)(Table 1). There did not appear to be a strong 
correlation between the bacterial load and function in any of the CD8 T cell groups. When there 
was a significant correlation, it was mostly early, at two weeks post-infection. No r
2
 coefficient 
approached 0.5, which we consider a relevant cut-off for significant correlation. 
In summary, there does not appear to be a strong correlation between bacterial load and 
the functions we studied when looking at a range of low-dose infections. This may, however, be 
due to the limited number of data points, despite pooling of data, or the relatively narrow range 
of bacterial inocula used. 
  
Lung Lymph node 
Function 
Weeks 
post-
infection 
Memory 
 
Primary 
with 
memory 
Primary 
without 
memory 
Memory 
 
Primary 
with 
memory 
Primary 
without 
memory 
IFN-γ 2 0.3667     0.1774   0.2315 
  4     0.1119       
  6       0.2010     
CD107 2 0.1342 0.1322   0.2670     
  4 0.3987           
  6 0.2596 0.1801     0.2956   
TNF 2     0.1933 0.1280   0.3350 
  4             
  6     0.1438       
IL-2 2 0.1886   0.3125 0.2667   0.1167 
  4   0.1588 0.1805       
  6     0.3799       
Table 1 Correlation between bacterial load and function. 
Data were pooled from eight independent experiments, with infection inocula ranging from 2-
150 CFU. Where there was a significant correlation between bacterial load and function 
(P<0.05), the correlation coefficients (r
2
) are shown to indicate the strenght of the correlation. 
Where the correlation between bacterial load and function were not significant (P>0.05), the 
boxes are grey.  
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4.3.3 Effect of memory cells on the quality of new CD8 T cell responses 
 To examine the effect of pre-existing memory cells on the quality of new CD8 T cell 
responses, we compared the function of cells primed in the presence and absence of memory. 
Cells primed in the presence of memory secreted more IL-2 and less TNF in both lungs (Figure 
13A and B) and lymph nodes (data not shown). However, there was little difference in the 
expression of IFN- and degranulation between the two groups in the lungs (Figure 13C and D) 
and lymph nodes (data not shown). No CD8 T cells were able to simultaneously degranulate and 
secrete IFN-, and there was no difference in the geometric mean fluorescence intensity of 
CD107, indicating that cytotoxicity was not affected by the presence of memory cells (data not 
shown). Other infection models have indicated that multifunctional T cells, i.e. cells able to 
simultaneously secrete IFN-, IL-2 and TNF, are more protective than T cells secreting fewer 
cytokines [82, 227], although this has not been definitively shown for M. tuberculosis [86, 116]. 
When we examined the frequency of IFN-+ CD8 T cells that were multifunctional, there were 
significantly more ova-specific CD8 T cells simultaneously secreting IFN-, IL-2 and TNF in the 
lungs when cells were primed in the presence of memory cells, while there was no significant 
difference in the lymph nodes (Figure 14).  
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Figure 13 Function of primary CD8 T cells, primed in the presence or absence of memory 
cells. 
A) IL-2 secretion, B) TNF secretion, C) IFN-γ secretion and D) degranulation by CD8 T cells in 
the lungs. White bars are CD8 T cells primed during secondary infection, while black bars are 
cells primed during primary infection. Cells primed in the presence of memory secreted 
significantly more IL-2 (P<0.006, week three post-infection) and IFN-γ (P<0.02, week six post-
infection), and significantly less TNF (P<0.002, week three post-infection, P<0.02, week four 
post-infection and P<0.004, week six post-infection). Data are the means ± standard errors of the 
means from test results for three mice per time-point.  
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Figure 14 Multifunctional CD8 T cells primed in the presence or absence of memory cells. 
Frequency of IFN-γ producing cells capable of simultaneously secreting IL-2 and TNF as well in 
the lungs (A) and lymph nodes (B) at four weeks post-infection. White bars are CD8 T cells 
primed during secondary infection, while black bars are cells primed during primary infection. 
IFN-γ producing cells primed in the presence of memory were significantly more multifunctional 
in the lungs (P<0.002), while there was no significant difference in the lymph nodes. Data are the 
means ± standard errors of the means from test results for three mice per time-point.  
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One possible difference between the CD8 T cells primed with and without memory cells 
is the quality of CD4 T cell help they receive. However, the requirement for and mechanism of 
CD4 T cell help appears to depend on the model system [88, 90, 228-230]. One mechanism is 
ligation of CD40L to CD40 on DC. This increases antigen-presentation and expression of co-
stimulatory molecules on the DC, which enables it to prime CD8 T cell responses [231]. 
However, activation of CD8 T cell responses during M. tuberculosis infection is independent of 
CD40L [40], as M. tuberculosis heat shock protein 70 serves as a ligand for CD40 [232]. Thus, 
other mechanisms of CD4 T cell help are more likely to be involved. Two alternative 
mechanisms of CD4 T cell help are secretion of IFN- [229] and IL-2 [230]. We therefore 
compared CD4 T cell cytokine production in primary and memory CD4 T cells and found that 
memory CD4 T cells expressed significantly more IFN- at 2 weeks post-infection (Figure 15A) 
and IL-2 at 4 weeks post-infection (Figure 15B) in the lungs. No significant difference was found 
in TNF expression. There was no significant difference in CD4 T cell function in the lymph 
nodes, where the cells are likely to be primed and where there is the greatest requirement for 
CD4 T cell help. However, memory cells respond faster than primary cells, and could thus 
provide increased CD4 T cell help in the lymph nodes during secondary infection, even though 
the cytokine profile is the same as that of primary CD4 T cells. 
In summary, CD8 T cells primed in the presence of memory secreted more IL-2, less 
TNF, and were more multifunctional. One possible mechanism of this observed difference is 
improved and earlier CD4 T cell help by memory CD4 T cells, which secreted IFN- earlier than 
CD4 T cells induced during primary response.  
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Figure 15 Cytokine production by CD4 T cells during primary and secondary infections. 
A) IFN-γ secretion, B) IL-2 secretion and C) TNF secretion by CD4 T cells in the lungs during 
primary infection (black bars) and secondary infection (white bars). Memory CD4 T cells 
secreted significantly more IFN-γ (P<0.01, week two post-infection) and more (P<0.03, week 
four post-infection) and less (P<0.008, week six post-infection) IL-2 than primary CD4 T cells in 
the lungs, while there was no significant difference in the lymph nodes. Data are the means ± 
standard errors of the means from test results for three mice per time-point.  
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4.3.4 Quality of memory and primary cells formed during acute infections 
We next examined whether altering the quality of the memory responses could influence 
the quality of newly primed CD8 T cells. This is based on work comparing chronic and acute 
LCMV infections in mice. Wherry et al. showed that LCMV-specific memory CD8 T cells 
generated during acute infection are functionally superior to those generated during chronic 
infection [233]. Thus, we examined whether the duration of primary M. tuberculosis infection 
influenced the quality of the memory CD8 T cell recall, and whether this in turn affected the 
quality of newly primed CD8 T cells. 
Our first strategy was to model an acute M. tuberculosis infection by initiating antibiotic 
treatment early (two weeks post-infection, "acute" group) instead of our standard late initiation 
(two months post-infection, "chronic" group). Bacteria were undetectable in lymph nodes by two 
weeks after the initiation of drug treatment and by four weeks in the lungs (Figure 15A and B), 
although both the acute and chronic groups were treated with antibiotics for three months to 
ensure that bacteria were cleared, based on previous experience. To study the development of 
memory CD8 T cells, we examined their function during antibiotic treatment, at eight weeks 
after initiation of drug treatment. Memory CD8 T cells developed similarly in both groups 
(Figure 16C and D), which indicates that shortening the primary infection did not dramatically 
alter the phenotype of the cells.  
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Figure 16 Clearing of bacteria and formation of memory cells during chronic and acute M. 
tuberculosis infections. 
(A and B) Antibiotic treatment cleared detectable bacteria at a similar rate in mice that had been 
infected for two weeks (black squares) and two months (open squares), while bacterial levels 
reached a plateau in the lungs (A) and lymph nodes (B) of untreated mice (circles). Memory cells 
formed during acute infection secreted significantly less IL-2 (P<0.01, lungs) and significantly 
more TNF (P<0.02, lungs) and IFN-γ (P<0.04, lymph nodes), but the overall functional 
phenotype of the cells was similar. Data are the means ± standard errors of the means from test 
results for three mice per time-point.  
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Upon re-infection, there was no significant difference in the bacterial load (Figure 17A 
and B) or in the function of the memory cells generated under acute and chronic conditions 
(lungs and lymph nodes, data not shown). While there was little significant difference in the 
quality of primary cells (Figure 17C to F), cells primed in the presence of acute memory cells 
secreted more IL-2 at 2 weeks post-infection. However, at this early time-point the primary 
response had not expanded significantly (Figure 10B), which questions the biological 
significance of this finding. Thus, shortening the primary infection did not significantly alter the 
quality of the memory CD8 T cells or the newly primed CD8 T cells. However, as elimination of 
both live mycobacteria (Figure 16A and B) and bacterial antigens [234] is slow, this is not a true 
model of acute infection.  
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Figure 17 Bacterial load and function of primary CD8 T cells upon re-infection of mice. 
The duration of the primary infection had no significant effect on the bacterial load of the lungs 
(A) or lymph nodes (B) when mice were re-infected with M. tuberculosis. There was also no 
significant difference in the quality of the primary CD8 T cell response in lung (C to F) or lymph 
nodes (data not shown) that was induced during the secondary infection, except for IL-2 
secretion (P<0.03, week 2 post-infection in lung). Data are the means ± standard errors of the 
means from test results for four mice per time-point.  
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Therefore, we next used a replication deficient adenovirus that expresses ova (Adeno-
ova) to model an acute primary infection. We intranasally infected mice with Adeno-ova and let 
the mice clear the infection for two months, after which we challenged the mice with M. 
tuberculosis-ova or Adeno-ova. Adeno-ova induced primary ova-specific CD8 T cells by 10 
days post-primary infection in the lungs (Figure 18A, 7 weeks before re-infection). Upon re-
infection with Adeno-ova, ova-specific CD8 T cells expanded by 7 days, and contracted by 14 
days. Little ova-specific response was seen in the lymph nodes (Figure 18B). When mice were 
re-infected with M. tuberculosis-ova (M.tb.), there was no significant difference in ova-specific 
recall whether the primary infection was with Adeno-ova or M. tuberculosis-ova (Figure 18A 
and B). Adeno-ova provided significantly less protection than M. tuberculosis-ova upon re-
infection with M. tuberculosis-ova (Figure 18C and D). This is likely due to induction of CD4 
and CD8 T cell memory to multiple antigens by M. tuberculosis-ova, while the majority of 
memory responses induced by Adeno-ova did not recognize mycobacterial antigens. 
Furthermore, there was no significant difference in the function of ova-specific memory cells 
induced by Adeno-ova and M. tuberculosis-ova infections (Figure 19). 
In summary, shortening the primary infection did not significantly alter the quality of the 
memory CD8 T cells or of the newly primed CD8 T cells.  
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Figure 18 Expansion and contraction of  ova-specific CD8 T cells in response to Adeno and 
M. tuberculosis infections. 
There was no significant difference in the expansion of ova-specific CD8 T cells whether the 
cells were induced during Adeno or M. tuberculosis infections (A and B, lung and lymph node, 
respectively). Memory responses induced by M. tuberculosis provided significantly more 
protection in both lung (C, P<0.04, week 1 post-infection and P<0.002, week 4 post-infection) 
and lymph node (D, P<0.0007, week 3 post-infection) than memory responses induced by 
Adeno. Data are the means ± standard errors of the means from test results for three mice per 
time-point. 
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Figure 19 Function of ova-specific memory CD8 T cells, primed during Adeno and M. 
tuberculosis infections. 
A) IFN-γ secretion, B) degranulation C) IL-2 secretion and D) TNF secretion memory CD8 T 
cells in the lungs during secondary infection with M. tuberculosis. White bars are CD8 T cells 
primed during Adeno infection, while black bars are cells primed during M. tuberculosis 
infection. There was no significant difference in function between the cells in the lungs (A to D) 
or lymph nodes (data not shown). Data are the means ± standard errors of the means from test 
results for three mice per time-point.  
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4.4 DISCUSSION 
In this study, we examined the effect of pre-existing memory cells on the number and 
function of new CD8 T cells primed during M. tuberculosis infection. Memory responses contain 
the bacterial infection around two weeks post-infection, as new CD8 T cell responses begin to 
expand. This decreases the inflammation and availability of antigen compared to a primary 
infection, where there are no memory cells. Our data show that a low bacterial load could prime 
CD8 T cells in the lymph nodes in the presence of memory. However, a sufficiently high 
bacterial load was required to induce new CD8 T cell responses in the lungs. The data indicate 
that cells are primed in the lymph node during secondary infection and subsequently migrate to 
the lungs. Anis et al. [235] showed that CD4 T cells are primed in the lymph nodes in response 
to intranasal delivery of antigen and that pulmonary inflammation (in their study BCG infection) 
is required for the cells to migrate to the lungs after priming. Thus, in our experiments the lack of 
ova-specific CD8 T cell responses in the lungs when bacterial load was low may be due to 
insufficient antigen or inflammation in the lungs. T cells primed in the absense of pre-existing 
memory cells were less dependent on the bacterial load, which may be due to increased 
inflammation and availability of antigen. Memory responses were also less dependent on the 
bacterial load, which likely reflects their lower dependency on antigen stimulation [236]. 
The data show that the presence of pre-existing memory during priming of new cells did 
not alter the frequency of cells that degranulated or secreted IFN-. However, the frequency of 
multifunctional IFN-+ cells increased, which indicates that the quality of the responding cells 
may be improved. The presence of memory also led to increased IL-2 secretion and decreased 
TNF secretion. Increased IL-2 production may be indicative of increased proliferative potential 
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of the cells, although cells primed in the presence and absence of memory reached similar 
numbers during the time-frame of this study (Figure 10 and Figure 12). Furthermore, loss of IL-2 
secretion has been shown to be an early event in CD8 T cell exhaustion during chronic viral 
infection [237]. Increased levels of IL-2 may thus be an early indicator of enhanced fitness of the 
cells. Increased IL-2 secretion has also been implicated in enhancing cytotoxicity of CD8 T cells 
by increasing the levels of perforin and granzymes, the effector molecules of cytotoxicity [238]. 
This will be a future area of study. 
TNF is secreted by many cell types during M. tuberculosis infection [239]. While TNF is 
important for containment of the bacterium, high levels are detrimental and lead to pathology 
[240]. Whether the decreased TNF expression by cells induced in the presence of pre-existing 
memory results in decreased histopathology is difficult to determine, however, as the early 
curtailment of bacterial expansion by the memory response results in decreased histopathology. 
While the current study focused on endogenous responses in their native setting, future studies 
will use adoptive transfer of cells to examine whether priming in the presence of memory leads 
to a biologically significant difference and examine a wider range of functions. 
Shortening the primary infection by early antibiotic treatment had surprisingly little effect 
on the quality of both the memory cells and primary cells. The data indicate that the chronicity of 
M. tuberculosis may not significantly influence the quality of the immune response, as has been 
suggested by some [102, 241]. Similarly, priming of ova-specific CD8 T cells by an acute 
heterologous infection did not significantly alter the ova-specific recall response to M. 
tuberculosis. 
The data show that there is significant interaction between primary and secondary 
immune cells during M. tuberculosis infection, and that memory cells can increase the quality of 
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the primary T cell response. However, the cells can also shape the environment, e.g. by early 
containment of bacterial expansion, so that new T cell responses are not induced in the lungs 
when the inoculum dose is too low. As the lungs are the site of infection, it is likely that the most 
protection would be derived from M. tuberculosis-specific immune responses localizing to the 
lungs. This may be one of the reasons why attempts to boost BCG vaccinations have largely 
failed in humans [159, 160], as the vaccine is given intradermally and may result in 
accumulation of memory cells in locations other than the lungs. This is supported by a study by 
Chen et al. who showed that intranasal BCG vaccination conferred superior protection compared 
to subcutaneous vaccination in mice [242]. Cumulatively, these data may lead to improved 
vaccination strategies against TB and a better understanding of what shapes the immune 
response to M. tuberculosis. 
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5.0  PRIMING OF MULTIFUNCTIONAL CD4 AND CD8 T CELLS DURING M. 
TUBERCULOSIS INFECTION IN MICE 
5.1 INTRODUCTION 
Neither M. tuberculosis infection nor BCG vaccination induce immune responses that 
reliably prevent establishment of infection or prevent re-infection. In fact, people who have 
successfully cleared the bacteria with antibiotics can be re-infected with M. tuberculosis and 
develop disease [219]. For these reasons, it has been suggested that mycobacterial vaccines may 
not be able to induce significantly protective immune responses against M. tuberculosis [80, 125] 
and that alternative vaccine strategies should be pursued, such as subunit vaccines and virally 
based vaccines [85, 86]. However, the BCG vaccine cannot be easily replaced due to the 
essential role that it plays in decreasing the severity of childhood TB. For this reason, much 
effort is being put into developing post-exposure vaccines, which boost immune responses 
induced by BCG and other mycobacteria. 
Despite the long coexistence of humans with M. tuberculosis, our understanding of the 
bacterium and the immune response required to contain the bacterium are limited. It is known 
that Th1-type immune responses, characterized by secretion of interferon-γ (IFN-γ) and tumor 
necrosis factor (TNF) by T cells, are essential for control of the bacterium [66, 243-246]. 
Furthermore, recently published work indicates that multifunctional T cells are beneficial [86, 
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116], as seen in other infection models [82, 227]. Multifunctional T cells are cells capable of 
simultaneously secreting IFN-γ, IL-2 and TNF. 
The aim of this study was to better understand what shapes the immune response to M. 
tuberculosis, and examine whether the functional phenotype of the immune response can be 
altered, without the use of adjuvants or viral vectors. To do this, we infected mice with M. 
tuberculosis-ova, a recombinant strain that expresses ovalbumin epitopes. We then adoptively 
transferred naive ova-specific CD4 and CD8 T cells into the mice at different times post-
infection and compared the responses to cells present from before infection. Our data show that 
the functional phenotype of the T cell response is not static, and that there is a significant 
difference in effector functions, depending on the environment in which the cell is primed. By 
manipulating the priming environment, we were able to significantly increase the percentage of 
multifunctional CD4 and CD8 T cells. Thus, while BCG provides necessary but insufficient 
protection, manipulation of the vaccination strategy may induce improved immune responses, 
without altering the bacterium. 
5.2 MATERIALS AND METHODS 
5.2.1 Mice 
B6.SJL-Ptprc
a
 Pepc
b
/BoyJ (CD45.1) and B6.PL-Thy1
a
/CyJ (Thy1.1) breeding pairs were 
obtained from Jackson Laboratories while C57BL/6 RAG1-/- background OTI and OTII T cell 
receptor transgenic mice were kindly provided by Louis D. Falo. The mice were bred at the 
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University of Pittsburgh Biotechnology Center and kept under specific pathogen-free conditions 
in a BSL3 facility. 
MACS cell separation technology (Miltenyi) was used to purify OTI and OTII cells from 
naive spleens. 5*10
3
 cells of each T cell receptor specificity were adoptively transferred in PBS 
to recipient mice by tail-vein injection. Experiments were performed at least twice, with three to 
four mice used per group/time-point/experimental procedure. The University of Pittsburgh 
Institutional Animal Care and Use Committee approved all animal protocols in this study. 
5.2.2 Bacterial infections 
Mice were infected with a low bacterial inoculum, using a nose-only exposure aerosolizer 
(Intox). Mice were infected with M. tuberculosis-ova [103], a recombinant M. tuberculosis 
Erdman strain that expresses ovalbumin epitopes recognized by CD8 T cells (OTI epitope, 257-
264) and CD4 T cells (OTII epitope, 323-339). 24 hours post-infection, whole lungs were 
homogenized and plated on 7H10 media agar (Difco) and incubated for three weeks at 37ºC, 5% 
CO2 to estimate the inoculum dose, 20-150 colony forming units (CFU) per lung. 
5.2.3 Single-cell suspensions 
To obtain single-cell suspensions of harvested tissues, lungs and lymph nodes were 
crushed through a 40-µm cell strainer with
 
a 5-ml syringe plunger. Bacterial load was determined 
by plating serial dilutions on 7H10 media agar plates. For the remainder of the samples, an 
NH4Cl-Tris solution
 
was used to lyse red blood cells, after which the cells were washed and 
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resuspended in T cell medium. Cells were counted and viability assessed using trypan blue 
exclusion (Sigma). 
5.2.4 Cytokine and chemokine analysis 
Tissues were crushed in 3ml of DMEM, cells pelleted and the tissue supernatants were 
filtered through a 0.45um syringe filter (Millipore). Bio-Plex beads (Bio-Rad) were used, 
according to manufacturer's instructions. Cytokines analyzed were: IL-1α, IL-1β, IL-2, IL-3, IL-
4, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-17, IFN-γ and TNF. Chemokines 
analyzed were: GM-CSF, MIP-1β, RANTES, MCP-1, VEGF. Samples were read on a Luminex 
100 IS Bio-Plex System machine (Luminex Corporation, Austin, TX). 
5.2.5 Flow cytometry 
Cells were incubated with CD8 ova (SIINFEKL) tetramer-phycoerythrin (Beckman 
Coulter) at 4ºC for 30 min in T cell medium. After washing, the cells were resuspended and 
incubated for 5 hours at 37ºC in T cell medium containing 3μM monensin (Sigma), anti-CD107a 
and CD107b fluorescein isothiocyanate antibody, anti-CD28 antibody (clone 37.51, 1μg/ml) and 
anti-CD3 antibody (clone 145-2C11, 0.1μg/ml) for nonspecific stimulation, or 4μg/ml OTI and 
OTII-specific peptides (GenScript) for ova-specific stimulation. 
Cells were washed in FACS buffer and surface-stained for 15 min with anti-CD8-pacific 
blue, anti-CD4-alexa fluor 700 and anti-CD45.2 or anti-Thy1.2 antibodies in 20% mouse serum 
(Gemini). The cells were then washed and fixed in 2% paraformaldehyde (Sigma). For 
intracellular staining, the cells were permeabilized in permabilization buffer and stained with 
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anti-IFN-γ-phycoerythrin-Cy7, anti-IL-2 Peridinin-chlorophyll Protein Complex (eBioscience) 
and anti-TNF-biotin. After washing, cells were stained with streptavidin-allophycocyanin-Cy7 
antibody. An LSRII (BD Biosciences) was used to read the samples, and the data were analyzed 
using FlowJo software (Tree Star). All antibodies were purchased from BD Biosciences, unless 
otherwise stated. 
5.2.6 In vivo cytotoxicity assay 
To measure ova-specific CD8 T cell mediated cytotoxicity, uninfected splenocytes were 
labeled with CFSE (Molecular Probes) at 0.4mM or 5mM concentrations for 15 min at 37ºC. 
Addition of T cell medium quenched the reaction, after which the cells were washed in 20% FBS 
in PBS. CFSE
low
 cells were pulsed for 1 hour with 20ug/ml SIINFEKL peptide (for ova-specific 
killing) or LCMV gp33-41 peptide (for controls) in PBS. CFSE
high
 cells were left unpulsed. 
CFSE
high
 and CFSE
low
 cells were mixed at a ratio of 1:1, and approximately 5*10
7
 cells 
injected by tail-vein injection into recipient mice. 18 hours later, mice were sacrificed and organs 
homogenized. The cells were washed in FACS buffer and fixed in 4% paraformaldehyde. 
A FACSCalibur (BD Biosciences) and FlowJo software were used to read and analyze 
the samples, respectively. 
%ova-specific lysis=100– 100*([%CFSEovalow/%CFSEhigh]/[%CFSELCMVlow/%CFSEhigh]). 
5.2.7 Priming of cells in vitro 
OTI and OTII cells were purified from naive transgenic mice on the RAG1-/- background 
using MACS cell separation technology, as described above. 5*10
4
 cells were incubated with 
 106 
tissue homogenates from infected mice. To obtain sufficient numbers, tissue homogenates from 
up to six mice were pooled, as needed. The cells were incubated for 5 days in T cell medium, 
without addition of any cytokines or antibiotics, after which they were stimulated and processed, 
as described in the flow cytometry section. 
5.2.8 Graphing and statistical analysis 
GraphPad Prism 4.01 (GraphPad Software) and SPICE 4.1.5 (developed by Mario 
Roederer, Vaccine Research Center, NIAID, NIH) were used for graphing and statistical 
analysis. Unpaired two-sided t test was used for parametric two-group analyses, while Mann-
Whitney t test was used for statistical analysis of bacterial load. ANOVA with Bonferroni post-
test was used for analysis of three and more groups. P values of <0.05 (*), <0.01 (**) and <0.001 
(***) were considered significant, highly significant and extremely significant, respectively. 
5.3 RESULTS 
5.3.1 Expansion and contraction of cells present before infection 
To follow the kinetics of the expansion and contraction of M. tuberculosis-specific cells, 
we adoptively transferred naive ova-specific cells from OTI and OTII mice to wild-type recipient 
mice prior to infection with M. tuberculosis-ova. To later identify the cells, the donor mice had a 
different congenic background (CD45.2 or Thy1.2) from the recipient mice (CD45.1 or Thy1.1). 
While host T cells can be renewed by emigration of naive T cells from the thymus, the 
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adoptively transferred cells do not have a source of renewal. Thus, we can follow their responses, 
from expansion to contraction. 
The OTI and OTII cells started to expand about two weeks post-infection and peaked 
around three to four weeks post-infection (Figure 20A and B, bars). Both OTI and OTII cells had 
contracted by six weeks post-infection, leaving a small fraction of the cells behind. There were 
significantly more OTI cells remaining than OTII cells in the lungs at six weeks post-transfer. 
The overall host CD4 and CD8 T cell responses continued to expand (Figure 20A and B, lines) 
in the lungs, while the cell numbers reached a relatively stable level in the lymph nodes. The data 
indicate that CD4 and CD8 T cell responses to M. tuberculosis are composed of overlapping 
waves of cells. Thus, as the infection went through different phases, cells were continuously 
being primed in different environments. In early infection, inflammation was low (Figure 21A 
and B) and there were low amounts of bacterial antigen. As the infection progressed, the 
bacterial load peaked at about three weeks post-infection (Figure 20C and D) and inflammation 
increased (Figure 21A and B). Chemokine expression increased as well (Figure 21C and D), 
which helped to recruit cells to the tissues, while there was an increase (IL-6 and IL-13) or 
decrease (IL-10) in the expression of anti-inflammatory cytokines and cytokines that skew the T 
cell response towards a Th2 response (Figure 21E and F). Further progression of infection 
resulted in more inflammation and expression of chemokines, and the amount of bacterial 
antigen was likely to be further increased despite control of bacterial expansion, as the clearing 
of mycobacterial antigens is slow [75]. 
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Figure 20 Expansion and contraction of adoptively transferred OTI and OTII cells in 
different environments. 
(A and B) Expansion and contraction of OTI (black bars) and OTII (white bars) cells, adoptively 
transferred before infection, in the lungs (A) and lymph nodes (B). For comparison, host CD8 
(black circles) and CD4 (white circles) T cell responses are shown in lines, with the right-hand 
scale. There were significantly more OTI cells remaining at six weeks post-infection in the lung 
than OTII cells (P<0.002), and host CD4 T cells responded faster than CD8 T cells (P<0.04, 
week 2 post-infection). (C and D) Live bacterial load peaked at three weeks post-infection in 
both the lungs (C) and lymph nodes (D) (P<0.05 and P<0.03, respectively). (E and F) Recovery 
of OTI and OTII cells adoptively transferred in at different times post-infection from the lungs 
(E) and lymph nodes (F). OTI cells (black bars) transferred in at three weeks post-infection 
expanded significantly more than OTI cells transferred in at other times (P<0.04 in lungs, P<0.02 
in lymph nodes), while there was no significant difference in the frequency of OTII cells (white 
bars). (G and H) Recovery of OTI (grey bars) and OTII (white bars) cells, transferred together or 
separately at three weeks post-infection. OTI cells expanded significantly more in both the lungs 
(G, P<0.03) and lymph nodes (H, P<0.0003) when they were transferred with OTII cells, while 
OTII cells expanded more in the lungs (P< 0.0005) and less in the lymph nodes (P<0.009) when 
they were transferred with OTI cells. Data are the means ± standard errors of the means from test 
results for four mice per time-point.  
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Figure 21 Cytokines and chemokines in infected organs. 
Protein levels of pro-inflammatory cytokines (A and B), chemokines (C and D) and anti-
inflammatory cytokines and Th2 cytokines (E and F) in tissue supernatants from the lungs (A, C 
and E) and lymph nodes (B, D and F), measured by Luminex. Results are shown for cytokines 
and chemokines with at minimum of 3-fold difference in levels between uninfected tissues and 
infected tissues. Data are the means ± standard errors of the means from test results for four mice 
per time-point. 
  
 111 
5.3.2 Expansion and contraction of cells transferred after infection 
We next examined expansion of cells that were adoptively transferred into mice at 
different times post-infection and recovered three weeks later. OTI cells transferred at three 
weeks post-infection expanded more than cells transferred at other times post-infection, as more 
cells were recovered from both lung and lymph node from this group (Figure 20E and F, black 
bars). Conversely, more OTII cells were recovered from lungs when cells were transferred later 
in infection, while there was no difference in numbers recovered from lymph nodes regardless of 
the timing of the transfer (Figure 20E and F, white bars). To examine whether OTI cell 
expansion was influenced by the presence of OTII cells, we transferred OTI and OTII cells, 
alone or together, at three weeks post-infection and examined the cell recovery (Figure 20G and 
H). OTI cells expanded significantly more when they were transferred with OTII cells, as more 
cells were recovered from both lung and lymph node. More OTII cells were recovered from lung 
when the cells were transferred with OTI cells, while fewer cells were recovered from the lymph 
node. This indicates that there is significant interaction between the cells, which influences their 
expansion. 
5.3.3 Function of OTI cells 
As we have shown previously [103], very few M. tuberculosis-specific CD8 T cells are 
able to both secrete IFN-γ and be cytotoxic. Instead, the cells are limited to either function, with 
the majority skewed towards cytotoxicity rather than secretion of IFN-γ. Cytotoxicity is 
indicated by surface expression of CD107, a lysosomal protein that is transiently exposed to the 
surface when lytic granules are released from the cell. To examine whether the phase of infection 
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influences the function of CD8 T cells, we compared the function of adoptively transferred OTI 
cells ("AT CD8"), transferred at different times post-infection, to endogenous ova-specific CD8 
T cell responses (Figure 22, "Host CD8"). Their function was examined three weeks after 
transfer, when the cells should have responded (as demonstrated in Figure 20A and B). 
As expected, host CD8 T cells were primarily cytotoxic (blue), with IFN-γ production 
(green) peaking early, at three weeks post-infection (first column of pie charts, Figure 22A and 
B). Very few cells were able to be both cytotoxic and secrete IFN-γ (red). OTI cells transferred 
before infection were almost exclusively cytotoxic (Figure 22C and D, first column of pie 
charts). When OTI cells were transferred after the peak of infection (six or fifteen weeks post-
infection), significantly more cells were skewed towards IFN-γ production than in the host CD8 
T cell response. As before, few, if any, cells were able to be both cytotoxic and secrete IFN-γ. 
The exception to this was cells adoptively transferred at three weeks post-infection (second 
column of pie charts), where unexpectedly some of the cells expressed both functions in the 
lungs and lymph nodes. 
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Figure 22 Cytotoxicity and secretion of IFN-γ. 
Surface expression of CD107, indicating cytotoxicity, and secretion of IFN-γ by host ova-
specific CD8 T cells ("Host CD8) in the lungs (A) and lymph nodes (B), as well as OTI cells 
("AT CD8", C and D), adoptively transferred at different times post-infection. 5*10
3
 OTI and 
OTII cells were adoptively transferred at 0, 3, 6 or 15 weeks post-infection, and were harvested 3 
weeks later. Green slices show cells that secreted IFN-γ, blue slices show cells that degranulated, 
and red slices show cells capable of both functions. OTI cells secreted significantly more IFN-γ 
than host CD8 responses when the cells were adoptively transferred at six and fifteen weeks 
post-infection (P<0.0003 and P<0.01 in the lungs, respectively, and P<0.0009 at week 6 in the 
lymph nodes). Significantly more cells were able to both secrete IFN-γ and degranulate when 
cells were transferred at three weeks post-infection (lymph node, P<0.01 AT vs Host, and 
P<0.01 week three post-infection AT vs other weeks AT). Data are the means from test results 
for four mice per time-point.  
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Cells which are able to simultaneously secrete IFN-γ, IL-2 and TNF (multifunctional 
cells) have been shown to correlate with increased protection in other infection models, and to 
secrete higher levels of cytokines than cells with fewer functions [82, 227]. As M. tuberculosis-
specific CD8 T cells can secrete all three cytokines, we examined the multifunctionality of the 
CD8 T cells (Figure 23). Our results indicate that very few host CD8 T cells are multifunctional 
(red), while OTI cells adoptively transferred in at three weeks post-infection or later can develop 
into multifunctional cells. Interestingly, all multifunctional cells transferred in at three weeks 
post-infection degranulated as well (data not shown). 
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Figure 23 Multifunctional OTI cells. 
Number of functions carried out by host CD8 T cells ("Host CD8) in lung (A) and lymph node 
(B) at different times post-infection, as well as the functions of adoptively transferred OTI cells 
("AT CD8", C and D), adoptively transferred at different times post-infection. 5*10
3
 OTI and 
OTII cells were adoptively transferred at 0, 3, 6 or 15 weeks post-infection, and were harvested 3 
weeks later. Blue slices show cells secreting one cytokine (IFN-γ, TNF or IL-2), green slices 
show cells that secrete two cytokines, and red slices show cells secreting all three cytokines. 
Cells transferred at week three post-infection were significantly more multifunctional than host 
cells (P<0.05 in lung and P<0.01 in lymph node). Data are the means from test results for four 
mice per time-point.  
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When we examined the geometric mean fluorescence intensity (GMFI) of cytokines 
produced by the cells (Figure 24), the multifunctional cells (black bars) expressed equal or 
higher levels of cytokines compared to other groups of cells. The largest difference was in the 
lymph nodes, where multifunctional cells expressed significantly more IFN-γ and TNF. 
Multifunctional cells in the lungs expressed significantly more TNF, but similar amounts of IFN-
γ and IL-2 compared to other cell groups.  
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Figure 24 Mean fluorescence intensity of cytokines secreted by OTI cells. 
Geometric mean fluorescence intensity (GMFI) of IFN-γ (A and B), TNF (C and D) and IL-2 (E 
and F) in cells making one cytokine (white bars), two cytokines (light grey and dark grey bars) or 
three cytokines (black bars) in the lungs (A, C and D) and lymph nodes (B, D and F). G is IFN-γ, 
2 is IL-2 and T is TNF. IFN-γ+IL-2+TNF+ ("G2T") OTI cells made significantly more IFN-γ 
(P<0.002 in lymph nodes,) and TNF (P<0.05 in lungs and P<0.0001 in lymph nodes) than other 
groups. Data are the means ± standard errors of the means from test results for four mice per 
time-point.  
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5.3.4 Function of IFN-γ+CD107+ OTI cells 
As transfer of OTII cells influences the expansion of OTI cells (Figure 20G and H), we 
next examined whether OTII cells influence the function of OTI cells as well. To do this, we 
adoptively transferred in OTI cells, with or without OTII cells, at three weeks post-infection and 
examined their ability to be cytotoxic and secrete IFN-γ (Figure 25). 
There were significantly more OTI cells capable of being cytotoxic and secreting IFN-γ 
when OTI and OTII cells were transferred together (Figure 25A and B). As TB is primarily a 
lung disease, we further examined the function of the cells in the lungs. The amount of IFN-γ 
produced on a per-cell basis was higher in IFN-γ+CD107+ cells (black bars) than in IFN-γ+ only 
cells (white bars) in both the lungs (Figure 25C) and lymph nodes (data not shown). 
Furthermore, the IFN-γ+CD107+ cells that developed when OTI and OTII cells were transferred 
together secreted more IFN-γ than cells developed when OTI cells were transferred alone. This 
did not hold true for lymph nodes, where OTI cells transferred without OTII cells made 
significantly more IFN-γ (data not shown). 
To study cytotoxicity of the cells in the lungs, we first examined the amount of CD107 
surface expression on a per-cell basis, as an indicator of how much the cells had degranulated 
during the stimulation period. Surprisingly, IFN-γ+CD107+ cells (black bars) degranulated less 
than CD107+ only cells (white bars) in the lungs (Figure 25D). The difference was less in lymph 
nodes, where degranulation and cytotoxicity are minor compared to the lungs (data not shown). 
Using the in vivo cytotoxicity assay, we measured CD8 T cell-mediated killing of target cells in 
mice that had received OTI cells, OTI and OTII cells, or had received a mock-transfer (PBS). 
Transfer of OTI cells alone increased cytotoxicity slightly compared to the mock-transferred 
group, while transfer of OTI and OTII cells, which is the condition that induces IFN-γ+CD107+ 
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cells, decreased cytotoxicity in all organs tested (Figure 25E and data not shown for lymph nodes 
and spleen). The data indicate that IFN-γ+CD107+ cells secrete more IFN-γ but are less 
cytotoxic than cells limited to either function. To examine whether this had a significant effect 
on the control of M. tuberculosis in the mice, we compared the bacterial load of the different 
groups of mice. There was no significant effect on the bacterial load in any examined organ in 
any of the groups when we examined them three weeks after transfer (Figure 25F, lung data 
shown) or six weeks after transfer (data not shown). 
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Figure 25 Effect of OTII cells on OTI cell function. 
(A and B) Development of IFN-γ+CD107+ OTI cells in the lungs (A) and lymph nodes (B) 
when OTI cells were transferred with or without OTII cells. There were significantly more IFN-
γ+CD107+ OTI cells in the lymph nodes when OTII cells were transferred as well (P<0.01). (C 
and D) Geometric mean fluorescence of cells with one (white bars) or both (black bars) functions 
in the lungs. (C) is the geometric mean fluorescence intensity of IFN-γ, while (D) is the 
geometric mean fluorescence of CD107. IFN-γ+CD107+ OTI cells made significantly more 
IFN-γ+ than cells limited to secretion of IFN-γ+ when OTI cells were transferred alone (P<0.05 
in lungs). Data are the means ± standard errors of the means from test results for three mice per 
time-point. (E) Killing of target cells at six weeks post-infection in mice who received OTI cells 
(grey bars), OTI and OTII cells (black bars) or PBS (white bars) at three weeks post-infection. 
Data are the means from test results for three mice per group. (F) Bacterial load in the lungs at 
six weeks post-infection in mice who received OTI (light grey bars), OTII (dark grey bars), OTI 
and OTII (black bars), or PBS (white bars) at three weeks post-infection. Data are the means ± 
standard errors of the means from test results for three mice per time-point.  
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5.3.5 Function of OTI cells primed in vitro 
To examine whether we could prime IFN-γ+CD107+ OTI cells in vitro, we incubated 
naive OTI cells with tissue homogenates from mice that had been infected for eleven days, three 
weeks, six weeks, eight weeks or were uninfected. Lung homogenates were able to prime IFN-
γ+CD107+ OTI cells, while lymph node homogenates did not (data not shown). No correlation 
could be found between the cytokine environment and priming of IFN-γ+CD107+ cells, using 
cytokine data from tissue homogenates in vivo (Figure 21) and from in vitro culture supernatants 
(data not shown). Furthermore, priming of IFN-γ+CD107+ OTI cells did not appear to be 
dependent on CD4 T cell help (data not shown). 
5.3.6 Function of OTII cells 
We next examined the secretion of IFN-γ, IL-2 and TNF by OTII cells, transferred with 
OTI cells (Figure 26, white bars) or alone (grey bars), and compared them to host CD4 T cell 
responses (black bars, mock transferred). As CD4 T cell-mediated IFN-γ secretion is essential 
for control of M. tuberculosis [79], we gated on IFN-γ positive cells and examined the 
expression of IL-2 and TNF within this gate. 
The peak of IFN-γ expression in mice is around three to four weeks post-infection [80, 
103]. The cytokine production by OTII cells transferred in before infection was similar to that of 
host CD4 T cells in both the lungs and lymph nodes when function was examined at three weeks 
post-infection (Figure 26A and B). However, when cells were transferred in at three weeks post-
infection, OTII cells secreted significantly more IFN-γ than the host CD4 T cells at six weeks 
post-infection, in both the lungs and lymph nodes (Figure 26C and D). The frequency of 
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multifunctional OTII cells was similar to the host CD4 cells when OTII cells were transferred 
before infection (Figure 26A and B). Conversely, a higher percent of OTII cells were 
multifunctional than host CD4 T cells when cells were transferred at three weeks post-infection 
(Figure 26C). Interestingly, transferring OTII cells with OTI cells caused a significant decrease 
in multifunctional OTII cells.  
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Figure 26 Function of OTII cells. 
OTII cells, transferred with (white bars) or without (grey bars) OTI cells. Host CD4 T cells from 
mock-transferred mice are shown for comparison (black bars). The data show cells who secrete 
IFN-γ ("G"), with or without IL-2 ("2") and TNF ("T). (A and B) are cells transferred before 
infection, and harvested at three weeks post-infection while (C and D) are cells transferred three 
weeks post-infection, and harvested at six weeks post-infection. OTII cells transferred with OTI 
cells at three weeks post-infection secreted significantly more IFN-γ alone (G) compared to the 
host CD4 T cell responses (P<0.02 in lungs and P<0.02 in lymph nodes), but less IFN-γ alone 
(P<0.02 in lymph nodes) and IFN-γ, IL-2 and TNF (G2T, P<0.05 in lungs) than cells transferred 
without OTI cells. OTII cells transferred alone at three weeks post-infection secreted 
significantly more IFN-γ (P<0.002 in lymph nodes), IFN-γ and TNF (GT, P<0.01 in lungs) and 
IFN-γ, IL-2 and TNF (P<0.04 in lungs) than host CD4 T cells. Data are the means ± standard 
errors of the means from test results for three mice per time-point.  
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When we compared the amount of cytokine produced, OTII cells transferred in at three 
weeks post-infection secreted higher levels of IFN-γ and TNF than OTII cells transferred in 
before infection (Figure 27A and B) in the lungs. There was no significant difference in IL-2 
secretion between the groups (Figure 27C). OTII cells transferred without OTI cells secreted 
more cytokines than cells transferred with OTI cells, of which multifunctional cells produced the 
highest amounts (green fragment). The same did not hold true for the lymph nodes (Figure 27D 
to F), where cells transferred before infection secreted higher levels of cytokines than cells 
transferred at three weeks post-infection. Cells transferred without OTI cells made significantly 
more IFN-γ and IL-2, but the highest amount of cytokines came from cells other than 
multifunctional cells (red, white and black).  
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Figure 27 Geometric mean fluorescence intensity of cytokines secreted by OTII cells. 
Geometric mean fluorescence intensity (GMFI) of IFN-γ ("G", A and D), TNF ("T", B and E) 
and IL-2 ("2", C and F) in OTII cells expressing one cytokine (black), two cytokines (white and 
red) or three cytokines (green) in the lungs (A to C) and lymph nodes (D to F). OTII cells were 
adoptively transferred, with or without OTI cells, either before infection or at three weeks post-
infection, and were harvested three weeks later. Data are the means ± standard errors of the 
means from test results for four mice per time-point.  
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5.4 DISCUSSION 
This study examined the effect of the environment on the functional phenotype of CD4 
and CD8 T cells during M. tuberculosis infection in mice. To study this, we infected mice with 
M. tuberculosis-ova, a recombinant strain that expresses ovalbumin epitopes which are 
recognized by T cell receptor transgenic CD4 (OTII) and CD8 (OTI) T cells, as well as by non-
transgenic T cells (host cells) [103]. Adoptive transfer of naive OTI and OTII cells into infected 
mice allowed us to examine the quantity and quality of the T cell response that developed. By 
transferring cells during different phases of infection, we show that the environment that the cells 
develop in can alter the functional profile of the cells. 
The role of CD4 T cells in controlling M. tuberculosis infection has been firmly 
established [79], while the role of CD8 T cells is less understood. CD8 T cells play a much 
smaller role in the mouse model of TB compared to nonhuman primates [104]. There are several 
possible reasons for this disparity, e.g. the murine lack of granulysin, a cytotoxic molecule that 
can kill M. tuberculosis. Thus it has been difficult using the mouse model of TB to establish 
which CD8 T cell functions are important in controlling M. tuberculosis bacterial growth or 
disease. However, Woodworth et al. [112] showed that CD8 T cell-mediated cytotoxicity 
appears to be an important function, as the bacterial load is higher in mice lacking cytotoxic 
molecules. CD8 T cell mediated IFN-γ secretion is also likely to be important, as CD8 T cells 
can compensate for the lack of IFN-γ in CD4 deficient mice by increasing their production, 
although this is not sufficient to save the mice [79]. We showed (chapter 3) that cytotoxicity and 
secretion of IFN-γ are carried out by distinct CD8 T cells during M. tuberculosis infection. The 
majority of the CD8 T cells are cytotoxic (CD107+), with IFN-γ secretion peaking at three to 
four weeks post-infection, after which CD8 T cell-mediated IFN-γ secretion is insignificant 
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[103]. When OTI cells were adoptively transferred prior to infection, the cells developed an 
almost exclusively cytotoxic phenotype. When cells were transferred into chronic infection, i.e. 
after bacterial expansion had been contained, significantly more OTI cells secreted IFN-γ than 
was observed in the host ova-specific CD8 T cell population. Interestingly, OTI cells that were 
adoptively transferred at the peak of infection, at three weeks post-infection, could both secrete 
IFN-γ and be cytotoxic. The IFN-γ+CD107+ cells were also multifunctional, i.e. they secreted all 
three cytokines examined, while very few host CD8 T cells were multifunctional. As has been 
shown in other infections, the multifunctional cells secreted higher levels of IFN-γ. However, the 
ability to secrete IFN-γ seems to impair the ability of the cells to be cytotoxic, as the cells 
degranulated less and were less cytotoxic in vivo. 
New CD8 T cells are presumably continuously primed during the infection, rather than 
cells being primed early in infection and expanding as necessary thereafter. This is supported by 
work published by Hoang et al. [102], who recently described an M. tuberculosis-specific CD8 T 
cell population that does not expand until late in infection. Thus, while both adoptively 
transferred OTI cells and host ova-specific CD8 T cells were presumably primed in the chronic 
phase of infection, their functional profiles differed. This disparity may be due to priming in 
different organs. The in vitro data indicate that CD4 and CD8 T cells can be primed in the lungs, 
as has been suggested by others [247], although this is a very artificial system where cells are in 
close proximity for extended periods of time and there is no influx of new cells. While lung 
homogenates were able to prime multifunctional OTI cells, the lymph node homogenates were 
not. This indicates that adoptively transferred cells may be partly or fully primed in the lungs, 
while host T cell responses are primed in the lymph nodes. To establish where the cells are 
primed, it will be important to identify better markers of priming. We have not found CD69, a 
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commonly used early activation marker [70, 71], to be a reliable marker of priming (unpublished 
data). Nor have we found proliferation to be useful, as the cells can be primed in one location 
and expand in another. Simultaneous transfer of OTI and OTII cells improved OTI cell function 
and expansion, which indicates that one of the limiting factors in CD8 T cell responses to M. 
tuberculosis may be the quality of the CD4 T cell help. CD4 T cell help was not required, 
however, when OTI cells were primed in vitro. This indicates that one function of CD4 T cells 
during M. tuberculosis infection is to recruit CD8 T cells to DC [248]; a function that is not 
required when cells are primed in vitro. 
As M. tuberculosis-ova induces weak host ova-specific CD4 T cell responses, we 
compared OTII responses to global CD4 T cell responses induced in the host. Host CD4 T cell 
responses were stronger at three weeks post-infection than at later time-points. This correlates 
with a peak in IFN-γ production in infected mice, as CD4 T cells are a major source of IFN-γ. 
There were no significant differences between OTII cells that were transferred before infection 
and the host CD4 T cell response. When OTII cells were transferred at three weeks post-
infection, significantly more OTII cells secreted IFN-γ than host CD4 T cells, and there were 
significantly more multifunctional cells in the lungs. OTII cells transferred at three weeks post-
infection secreted more cytokines on a per-cell basis in the lungs than cells transferred before 
infection, the majority of which came from multifunctional cells, and the cells expanded more. 
This did not hold true for OTII cells in the lymph nodes, where OTII cells transferred at three 
weeks post-infection expanded less, and more cytokines were made by cells transferred before 
infection, most of which came from cells with two functions rather than multifunctional cells. 
Due to the discrepancy in OTII cell behavior between the lungs and lymph nodes, which was not 
reproduced in OTI cells, it is unclear whether the focus of CD4 T cell priming should be on the 
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lung or the lymph node, as they both play an important role. The lymph node is a source of long-
lived central memory cells which provide long-term protection, while the lung is the source of 
effector cells and effector memory cells, which are the first cells to respond during infection 
[249]. Simultaneous transfer of OTI and OTII cells appeared to be detrimental to OTII function. 
As OTI and OTII epitope expression and presentation is likely to be parallel, OTI cell-mediated 
cytotoxicity could kill the antigen presenting cells, thus limiting the availability of OTII antigens. 
Alternatively, the presence of OTI cells may directly suppress OTII function, or skew OTII 
function towards a function that was not examined in these studies. 
Collectively, the data indicate that both the environment and the quality of the CD4 T cell 
help contribute to priming of CD8 T cells. The conditions for CD8 T cell priming are optimal at 
the peak of infection, resulting in more cellular expansion, more multifunctional cells and the 
ability to be both cytotoxic and secrete IFN-γ. Priming of CD4 T cells at the peak of infection 
can also increase the frequency of multifunctional CD4 T cells compared to host CD4 T cells. 
However, the presence of CD8 T cells appears to decrease the quality of the CD4 T cell 
response. The data indicate that the immune response to M. tuberculosis can be broadened to 
induce multifunctional CD4 and CD8 T cells, without manipulation of the bacterium. This 
experimental model may prove useful for development of TB vaccine strategies, by allowing 
dissection of how the environment influences the function of the cells. 
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6.0  QA-1 DOES NOT PLAY A SIGNIFICANT ROLE IN MURINE M. 
TUBERCULOSIS INFECTION. 
6.1 INTRODUCTION 
As discussed in Chapter 1.2, there are approximately 2 billion people chronically infected 
with M. tuberculosis, in spite of induction of apparently robust immune responses. At present, it 
is not known why the bacterium is able to persist. It has been hypothesized that the immune 
response is titrated, so as to contain the bacterial infection while limiting the damage incurred by 
the immune response [250, 251]. While this may be beneficial to the infected individual, it 
results in an enormous reservoir of people harboring bacteria who can reactivate and become 
infectious. 
To examine possible mechanisms of M. tuberculosis persistence, we looked towards 
other infections where the immune response allows the microbe to chronically persist. Notably, 
ocular infection with herpes simplex virus-1 (HSV-1) causes a chronic infection in the peripheral 
nervous system, characterized by an active CD8 T cell response [252, 253]. Liu et al. showed 
that CD8 T cells control HSV-1 replication in the trigeminal ganglia by secreting IFN-, thus 
preventing the virus from killing the host cells [254]. Conversely, Suvas et al. showed that Qa-1 
expression by infected cells suppressed their killing by CD8 T cells, thus allowing the virally 
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infected cells to persist. However, high levels of viral antigen can override this suppressive effect 
[252]. 
Qa-1 is a nonclassical MHC class I molecule that can present endogenous and exogenous 
peptides [255, 256]. The leader sequence of classical MHC class I molecules (Qdm) has optimal 
binding properties to Qa-1 [257, 258]. Qa-1 can be bound by NKG2 molecules on natural killer 
(NK) cells and CD8 T cells (Figure 28A). [259, 260] Of them, NKG2A is the predominant 
binding partner [257], sending a suppressive signal and preventing release of cytotoxic granules 
[261]. Qa-1 can also be bound by the T cell receptor in an antigen-specific manner (Figure 28B) 
[256, 262].  
 
Figure 28 Qa-1 binding partners. 
Qa-1 can bind A) NKG2 receptors or B) CD8 T cell receptor. The green cells depict monocyte-
derived cells, infected with M. tuberculosis (red ovals). The red and blue cells depict CD8 T 
cells, whose function is suppressed or induced, respectively. 
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Presentation of peptides from the CD4 T cell receptor can lead to killing of CD4 T cells 
by CD4 T cell-specific CD8 T cells. This has been exploited in T cell vaccinations, where self-
reactive CD4 T cells can be selectively killed by CD8 T cells, resolving diseases like 
experimental autoimmune encephalomyelitis [263]. Peptides from infectious agents can also be 
presented in Qa-1 (including Salmonella typhimurium [255] and Listeria monocytogenes [220]), 
or in the human homolog, HLA-E (including cytomegalovirus [264] and M. tuberculosis [265]). 
HLA-E-restricted M. tuberculosis-specific human CD8 T cell lines have been shown to be 
cytotoxic and secrete IFN-γ [265]. This indicates that murine Qa-1 may present M. tuberculosis 
antigens to CD8 T cells. This could either result in functional M. tuberculosis-specific CD8 T 
cells or give suppressive CD8 T cells, i.e. CD8 T cells reactive for CD4 T cells or cells receiving 
suppressive signals through the NKG2A receptor. 
In this study, we hypothesized that Qa-1 plays a role in M. tuberculosis persistence by 
suppressing cytotoxicity through NKG2A association. To test this, we compared T cell responses 
and bacterial loads in WT mice and mice lacking Qa-1 (Qa-1-/-). Our results indicate that despite 
increased Qa-1 expression by DC and Mɸ following M. tuberculosis infection, expression of Qa-
1 is neither beneficial nor detrimental to the mice. 
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6.2 MATERIALS AND METHODS 
6.2.1 Mice and bacterial infections 
Six to eight week old C57BL/6 mice were obtained from Jackson Laboratories. Robert L. 
Hendricks kindly provided a Qa-1-/- breeding pair, with the permission of Harvey Cantor. Qa-1-
/- mice were bred at the University of Pittsburgh Biotechnology Center and kept in a BSL3 
facility, under specific pathogen-free conditions. Mice were aerosol infected using nose-only 
exposure as in [36], with M. tuberculosis (Trudeau Institute). Whole lung homogenate was plated 
24 hours post infection to determine the bacterial inoculum, estimated to be 2-10 colony forming 
units (CFU) per lung. 4 mice were used per group per time-point. Experiments were performed 
at least twice. The University of Pittsburgh Institutional Animal Care and Use Committee 
approved all protocols used in this study. 
6.2.2 Harvesting cells from organs 
 Single-cell suspensions were obtained, as in [103]. Serial dilutions of organ homogenates 
were plated on 7H10 media agar (Difco) and cultured for 3 weeks at 37ºC 5% CO2 to determine 
the bacterial load. The samples were processed and live cells counted, as in [103]. 
6.2.3 ELISpot assay 
DC were cultured from bone-marrow [103] and were used to present antigen in ELISpot 
assays. DC were infected at a multiplicity of infection of 3 for 24 hours (to examine global M. 
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tuberculosis-specific responses), were pulsed with 4μg/ml peptide (GenScript) (to examine 
single antigen-specific responses) or were left uninfected and unpulsed (to measure background 
level IFN-γ secretion). 
ELISpot plates (MultiScreen HTS 96-well, Millipore) were coated and cells co-cultured 
for 48 hours with DC, as in [103]. Detection of IFN-γ and counting of spots was performed as in 
[103]. 
6.2.4 Flow cytometry 
For surface expression, cells were washed in FACS buffer. The cells were then stained in 
staining buffer (FACS buffer containing 20% mouse serum [Gemini]) with anti-CD11c-PE-Cy7, 
anti-CD11b-PerCP, anti-Gr-1-APC and anti-Qa-1-biotin followed by anti-strepavidin-APC-Cy7 
antibody. Cells were then washed and fixed in 4% paraformaldehyde (Sigma). 
For functional characterization, cells were incubated for 30 min at 4ºC with GAP 
(GAPINSATAM) tetramer-PE (Beckman Coulter) in T cell medium. The cells were then washed 
and incubated for 5 hours at 37ºC in T cell medium with 3μM monensin (Sigma) and anti-
CD107a and b FITC antibody. Cells were nonspecifically stimulated with -CD28 (clone 37.51, 
1μg/ml) and anti-CD3 (clone 145-2C11, 0.1μg/ml) as well as specifically stimulated with 4μg/ml 
GAP peptide (Genscript). Cells were then washed in FACS buffer and stained in staining buffer 
with anti-CD8 PerCP for 15 minutes. The cells were then washed and fixed in 2% 
paraformaldehyde. Permeabilization buffer was used to permeabilize the cells, who were 
subsequently and stained with anti-IFN--PE-Cy7. 
FACS Aria (BD Biosciences) was used to read the samples, and data was analyzed with 
FlowJo (TreeStar) software. Antibodies were from BD Biosciences, unless otherwise stated. 
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6.2.5 In vivo cytotoxicity assay 
Uninfected splenocytes were labeled with CFSE (Molecular Probes, Eugene, OR) and 
pulsed with peptide (GAP for antigen-specific killing, LCMV gp33-41 for controls), as in [103]. 
CFSE
high
 and CFSE
low
 cells were mixed at a ratio of 1:1 and approximately 5*10
7
 cells injected 
into mouse tail veins (4 mice/group/time-point). 18 hours later, mice were sacrificed and lung 
and spleen homogenates harvested. Cells were washed in FACS buffer and fixed in 4% 
paraformaldehyde. FACSCalibur (BD Biosciences) was used to read samples, and FlowJo 
software used to analyze the data. 
%GAP-specific lysis = 100 – 100*[(%CFSEGAPlow/%CFSEhigh)/(%CFSELCMVlow/%CFSEhigh)] 
6.2.6 Statistical analysis 
Graphing and statistical analysis were performed using GraphPad Prism 4.01 (GraphPad 
Software). Unpaired two-sided t tests were used for two-group analysis. P values of <0.05 were 
considered significant (*). 
6.2.7 Histology 
Lung lobes were fixed in 10% normal buffered formalin and then embedded in paraffin. 
5-6 µm sections were cut and stained with Harris' hematoxylin and eosin. 
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6.3 RESULTS 
6.3.1 Qa-1 expression 
Qa-1 expression increased on both DC (DC, CD11c+) and Mɸ (CD11c-CD11b+Gr-1-) in 
the lungs of WT mice following M. tuberculosis infection (Figure 29). This increase is likely due 
to increased availability of peptide suitable for presentation by Qa-1 [258]. However, it is 
unknown which peptides are presented following M. tuberculosis infection, and whether there 
are changes in peptide presentation over time. 
 
Figure 29 Qa-1 expression on DC and Mɸ following M. tuberculosis infection. 
Data are mean ± standard error of mean (SEM) of 4 mice per time-point.  
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6.3.2 Role of Qa-1 in priming of CD8 T cells 
T cells can be primed in the lymph node and then migrate to the lungs to fight the 
infection [251]. There was no significant difference in the number of cells recovered from WT 
and Qa-1-/- mice, except a single time-point in two of three experiments. In these experiments, 
there were significantly more cells in WT lymph node 6 weeks post-infection (Figure 30) or 9 
weeks post-infection (data not shown), but in both cases this difference did not carry over to the 
lungs.
 
Figure 30 Live cells recovered from lung and lymph nodes of M. tuberculosis infected mice. 
There was no significant difference in the number of cells between WT and Qa-1-/- mice in A) 
lung, while there was a significant difference in B) lymph node at 6 weeks post-infection. Data 
are mean ± SEM of 4 mice per time-point. 
 
There was no significant difference in the ratio of CD4 and CD8 T cells in the 
lymphocyte gate between WT and Qa-1-/- mice (Figure 31), except for CD4 T cells at 9 weeks 
post-infection and CD8 T cells at 3 weeks post-infection in the lungs. Additionally, upon 
repetition there was no significant difference in the lungs between the two mouse strains (data 
not shown). While a decreased CD4 T cell frequency and increased frequency of CD8 T cells in 
the lymphocyte gate could indicate that Qa-1 expression led to priming of CD8 T cells (either 
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CD4 T cell-specific or M. tuberculosis specific) in the WT mice, the brief duration of the 
difference would argue against a significant biological impact.  
 
 
Figure 31 Percent CD4 and CD8 T cells in lymphocyte gate. 
There was no significant difference in the frequency of A and B) CD4 T cells and C and D) CD8 
T cells in the lung A, C) and lymph node B, D), except for CD4 T cells at 9 weeks post-infection 
and CD8 T cells at 3 weeks post-infection in the lung. Data are mean ± SEM of 4 mice per time-
point. 
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When GAP-specific CD8 T cells were examined using tetramers, there was no significant 
difference in percent GAP cells between the two strains (Figure 32). Collectively, these data 
indicate that Qa-1 did not play a significant role in inducing CD8 T cell priming, whether it was 
against M. tuberculosis antigens or against CD4 T cell receptor. 
 
 
Figure 32 Percent GAP-specific CD8 T cells. 
There was no significant difference between WT and Qa-1-/- mice in either A) lung or B) lymph 
node. Data are mean ± SEM of 4 mice per time-point. 
6.3.3 Role of Qa-1 on CD8 T cell function 
Multicolor flow cytometry was used to examine CD8 T cell function on a single cell 
basis. Our results indicate that Qa-1 expression did not have a significant effect on function in 
the lungs (Figure 33 and Figure 34) or lymph nodes (data not shown). There was no significant 
difference in degranulation (measured by surface exposure of CD107 molecules) or IFN-γ 
production between the two mouse strains, whether we examined total CD8 T cell responses 
(Figure 33) or a population of M. tuberculosis-specific cells (GAP-specific CD8 T cells, data not 
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shown). 
 
Figure 33 Degranulation and IFN-γ secretion. 
A) CD107 surface expression and B) IFN-γ secretion, measured by flow cytometry. There was 
no significant difference between WT and Qa-1-/- mice. Data are mean ± SEM of 4 mice per 
time-point. 
 
 
Figure 34 Functional assays. 
A) IFN-γ ELISpot assay, measuring IFN-γ secretion in lung in response to M. tuberculosis. Data 
are mean ± SEM of 4 mice per time-point. B) GAP-specific cytotoxicity in lung. Data is an 
average of 4 mice per group per time-point. 
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6.3.4 Bacterial load and pathology 
There was no significant difference in bacterial load between the two strains (Figure 35), 
indicating that if Qa-1 primed M. tuberculosis-specific cells, these cells did not contribute 
significantly to control of the bacterium. Histological analysis of the lung indicated that there 
was not a significant difference in inflammation and granuloma formation between the two 
mouse strains (Figure 36). 
 
Figure 35 Bacterial load in lung. 
There was no significant difference between the two mouse strains. Data are mean ± SEM of 4 
mice per time-point. 
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Figure 36 Lung pathology. 
5 weeks post-infection, a lobe of lung from A) WT and B) Qa-1-/- mice was fixed in 10% 
formalin and then embedded, sectioned and stained with hematoxylin and eosin. 10x 
magnification. 
6.4 DISCUSSION 
In this study, we examined whether Qa-1 plays a role in the immune response during 
murine M. tuberculosis infection. Qa-1 has been shown to contribute to viral persistence in 
chronic viral infections, e.g. HSV-1, where Qa-1 was shown to suppress cytotoxicity while 
allowing CD8 T cells to secrete IFN-γ [252]. Studying Qa-1 is complicated by the fact that it can 
be bound by both T cell receptor and NKG2 molecules, with both immunostimulatory and -
suppressive effects, depending on the binding partner and the peptide [266]. 
We hypothesized that Qa-1 would bind NKG2A and suppress cytotoxicity during M. 
tuberculosis infection in mice. However, there was no significant difference in degranulation or 
secretion of IFN-γ between WT mice and mice deficient in Qa-1. The in vivo cytotoxicity assay 
indicated that Qa-1 did not suppress cytotoxicity, as cytotoxicity in WT mice was equal or 
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greater. However, for technical reasons we used GAP peptide pulsed targets instead of M. 
tuberculosis infected cells for this assay, which could affect the results as target cells may not 
express Qa-1. Taken together, our results indicate that Qa-1 did not have a significant 
suppressive effect on CD8 T cell function or affect bacterial survival.  
An alternative hypothesis was that Qa-1 would bind T cell receptor and induce CD8 T 
cell responses. This was based on data showing that HLA-E, the human homolog of Qa-1, can 
present M. tuberculosis antigen to CD8 T cells [265]. The outcome of antigen presentation by 
Qa-1 depends on which antigen is presented. Jiang et al. have shown that presentation of 
peptides from CD4 T cell receptor can lead to CD8 T cell mediated killing of CD4 T cells [267]. 
This does not appear to be the case in murine M. tuberculosis infection, as we see normal 
numbers of CD4 T cells. Alternatively, presentation of bacterial antigens could lead to priming 
of functional M. tuberculosis-specific CD8 T cells. Without knowledge of the antigen, we do not 
have tetramers to identify these cells. For this reason, we examined total CD8 T cell responses, 
or GAP-specific cells. Neither total CD8 T cell responses nor GAP-specific responses were 
significantly different between the mouse strains, indicating that if Qa-1 primes M. tuberculosis–
specific CD8 T cells in mice, then this population is not immunodominant and does not have a 
significant effect on the course of the infection. 
In conclusion, our study indicates that Qa-1 does not have a significant effect on the 
course of M. tuberculosis infection in mice. 
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7.0  SUMMARY OF THE THESIS 
Tuberculosis (TB) is, for the most part, a treatable disease. Despite this, approximately 
two million people die of TB every year, the majority of whom are in developing countries. 
Control of the TB epidemic in more affluent countries gave the misperception that TB no longer 
posed a serious health threat to humans. However, immunosuppression due to HIV infection and 
immunosuppressive therapies, e.g. in patients with autoimmune diseases, have caused a 
resurgence of TB in wealthy places such as New York city [268, 269] and have brought TB back 
to our attention. The impact of TB on human health in less developed nations remains as serious 
as ever. 
While M. tuberculosis-specific T cells are essential for controlling the bacterium, it 
appears that they are unable to prevent the establishment of infection and clear the bacteria [103, 
270]. Similarly, protection conferred by memory cells is limited, as persons vaccinated with 
BCG or treated for TB with antimycobacterial drugs can be infected and re-infected with M. 
tuberculosis and develop disease [219]. A major hurdle in improving TB vaccines has been the 
lack of understanding of what constitutes an effective immune response to the bacterium, and 
how such an immune response can be achieved. In this thesis, we have focused our studies on the 
function and regulation of CD8 T cells during murine M. tuberculosis infection. 
Relatively little was known about the function of M. tuberculosis-specific CD8 T cells 
when we started this work five years ago. One reason for this was the belief that CD8 T cells do 
 145 
not contribute significantly to the control of M. tuberculosis [81, 113], which has since been 
conclusively disproven [104]. Another reason was the dearth of known bacterial epitopes 
recognized by CD8 T cells [100]. Several epitopes have since been identified, some of which 
induce CD8 T cell responses early in infection [101, 271], while others induce responses later in 
infection [102, 272]. Identification of these epitopes have allowed characterization of CD8 T cell 
responses to single antigens and utilization of many immunological techniques, such as the in 
vivo cytotoxicity assay, that were previously unavailable. In our studies, we made extensive use 
of one of the CD8 T cell epitopes, referred to as GAP [273], which appears to be expressed 
throughout infection. Development of a recombinant M. tuberculosis strain that expresses 
ovalbumin epitopes [103] further expanded the available tools for studying M. tuberculosis-
specific CD8 T cells, and proved to be a great boon to our research. Using the recombinant 
bacteria, we were able to study the effect of various factors, such as interactions with pre-
existing memory cells, the quality of CD4 T cell help and the environment, on the function of 
CD8 T cells in vivo. 
We first characterized the M. tuberculosis-specific CD8 T cell response during primary 
and secondary infections using multicolor flow cytometry. We found that cytotoxicity and 
secretion of IFN- were carried out by distinct CD8 T cells, with the majority of the cells being 
cytotoxic. This contrasted with data published on CD8 T cells specific for other infectious 
agents, such as HIV [227], where cells could simultaneously carry out both functions. This held 
true for both primary and secondary infections, and indicated that there was a functional defect in 
CD8 T cells induced during M. tuberculosis infection. Also, it indicated that detection of IFN- 
secretion is an insufficient means of studying CD8 T cell responses to M. tuberculosis as only a 
minority of the cells secrete IFN-, even though this is the easier and most common method for 
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studying human CD8 T cell responses in TB and other infections. When we compared primary 
and memory CD8 T cell responses, we found that the primary cells secreted higher levels of 
IFN-. Additionally, even though the frequency of degranulating cells and the amount of 
degranulation on a per-cell basis was higher in the memory cells, the primary cells were more 
cytotoxic. This indicates that there is a defect in cytotoxicity in the memory cells, although 
expression of cytotoxic molecules that are stored in the vesicles was comparable to expression in 
primary CD8 T cells. Collectively, this indicated that although memory cells respond faster than 
primary cells, the primary cells are more functional than memory cells. 
We hypothesized that IFN- secretion and cytotoxicity being carried out by distinct CD8 
T cells was the consequence of either cellular exhaustion or the regulation by an inhibitory 
molecule. CD8 T cells can become exhausted during chronic viral infections, in that they lose 
effector functions such as secretion of IFN- [274]. One marker of exhaustion is chronic high 
expression of PD-1, although other markers exist as well [275]. However, PD-1 expression was 
not chronically high on M. tuberculosis-specific CD8 T cells, and blocking interactions between 
PD-1 and its ligands had no significant effect on the function of CD8 T cells or the bacterial 
burden of the mice. The same held true for Qa-1, a nonclassical MHC class I molecule, which 
inhibits CD8 T cell-mediated cytotoxicity in herpes simplex virus-1 (HSV-1) infected mice while 
allowing secretion of IFN- [252, 254]. When we infected mice deficient in Qa-1 with M. 
tuberculosis, we found no significant effect on CD8 T cell responses or bacterial load compared 
to WT mice. Thus, cytotoxicity and secretion of IFN- being carried out by distinct CD8 T cells 
during M. tuberculosis infection does not appear to stem from exhaustion or inhibition by Qa-1. 
To further examine the regulation of CD8 T cells, we examined what effect the presence 
of pre-existing memory cells had on the quality and quantity of newly primed CD8 T cells. 
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Infants in TB endemic areas are vaccinated with BCG, which induces memory responses that are 
cross-reactive with M. tuberculosis. As the children progress to adolescence and young 
adulthood, the likelihood of progressing to TB increases precipitously. Much effort is being put 
into developing post-exposure vaccines to boost the immune responses induced by BCG, in the 
hope that adolescents and young adults may be protected. As boosting with BCG has been 
unsuccessful [159], some new vaccine candidates contain M. tuberculosis antigens that are not 
present in the BCG vaccine [175] in addition to antigens that are cross-reactive between the 
bacteria. If successful, the immune response would consist of a combination of primary T cells 
and memory T cells. However, it has been shown in other infections that memory cells can 
influence the quality and quantity of primary cells, e.g. by providing CD4 T cell help or by 
inhibiting priming of new CD8 T cells [220-225]. 
Thus, in chapter four, we examined the effect of memory cells (GAP-specific cells) on 
the quantity and quality of primary cells (ova-specific cells). While the mice induced ova-
specific CD8 T cell responses in the lymph nodes, we found that a sufficient bacterial burden 
was required for ova-specific responses to appear in the lungs, the primary site of infection. This 
indicates that memory cells contained the bacterial infection before new CD8 T cells had 
migrated to the lungs in the mice with the lowest bacterial load. This has implications for human 
vaccinations, as BCG-specific memory cells may prevent induction of strong primary M. 
tuberculosis-specific CD8 T cell responses in the lungs by the new vaccine candidates. 
On the other hand, memory cells also influenced the quality of the primary response, in 
that the primary cells secreted higher levels of IL-2, a cytokine associated with proliferation and 
enhanced cytotoxicity [238]. They also secreted lower levels of TNF, a cytokine that is essential 
for control of M. tuberculosis, but high levels can cause tissue pathology [240]. While memory 
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cells did not affect cytotoxicity or the frequency of cells secreting IFN- in the primary response, 
they did enhance the multifunctionality of the cells secreting IFN-, which appears to correlate 
with increased protection in other infection models [82-84]. This indicates that memory cells can 
influence both the magnitute and quality of primary CD8 T cell responses. 
In chapter five, we used adoptive transfer of naive ova-specific CD4 and CD8 T cells to 
examine what effect the environment had on the quality of the CD8 T cell response. We showed 
that CD8 T cells primed after mice were infected with M. tuberculosis secreted significantly 
more IFN- than CD8 T cells that were present before the infection. Furthermore, CD8 T cells 
primed at the peak of infection (three weeks post-infection) were significantly more 
multifunctional than cells primed at other times. Additionally, the multifunctional cells could 
simultaneously secrete IFN- and be cytotoxic. Thus the functional phenotype of CD8 T cells 
can be dramatically altered by the environment that cells are primed in, although the specific 
factors that determine cellular function have not been identified. CD4 T cell help appeared to be 
important for the development of multifunctional CD8 T cells, as CD8 T cells transferred 
without CD4 T cells had significantly fewer functions and secreted lower amounts of cytokines. 
Transfer of CD4 T cells during the peak of infection also resulted in more multifunctional 
cells, compared to host CD4 T cell responses in the lungs. However, simultaneous transfer of 
CD8 T cells appeared to be detrimental to priming of multifunctional CD4 T cells. This indicates 
that there is significant bidirectional interaction between CD4 and CD8 T cells during M. 
tuberculosis infection that needs to be further examined. 
Collectively, the data presented in this thesis indicate that M. tuberculosis-specific CD8 T 
cell responses are complex, and that the response is influenced by various factors, such as the 
priming environment and the quality of CD4 T cell help. The data also indicate that the immune 
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response to the bacterium can be manipulated to generate more functional T cells, without 
altering the bacterium, by altering the environment in which the cells are primed. This has 
important implications for vaccination against the bacterium, as the current vaccination protocols 
only provide partial protection. While it has still not been established what constitutes a 
protective immune response to the bacterium, it is our hope that the data presented here may lead 
to advances in development of new TB vaccines, as well as an improvement in efficacy of the 
existing vaccine, and a better understanding of what shapes the immune response to M. 
tuberculosis. 
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APPENDIX A- SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1 M. tuberculosis-ova induces similar GAP- and ova-specific 
responses. 
Percent tetramer positive CD8 T cells in A) lung and B) lymph node during primary (1’) and 
secondary (2’) infections were significantly different 0, 3 and4 (lung), 2 and 3 (lymph node) 
weeks post-infection for ova-specific cells (o*) and 0, 3 and 4 (lung), 3 and 4 (lymph node) 
weeks post-infection for GAP-specific cells (g*). The frequency of ova and GAP-specific cells 
was significantly different 4 and 8 (lung), 3 and 28 (lymph node) weeks post-primary infection 
(go1*). Data are mean ± SEM of 4 mice per time-point.  
 151 
 
Supplementary Figure 2 Representative dot plots and geometric mean fluorescence 
intensity. 
A) and D) are CD107 versus IFN- staining. D) is from a mouse that was treated with anti-PD-1 
and anti-PD-L1 antibodies for 4 weeks, while A) was untreated. B) and C) show IFN- staining 
of GAP+ CD8 T cells, 4 weeks post-primary (B) and secondary (C) infection in lung. (E and F) 
show CD107 staining of GAP+ CD8 T cells, 4 weeks post-primary E) and secondary F) infection 
in lung. G) shows geometric mean fluorescence intensity of PD-1 staining on OTI cells in lung, 2 
and 4 weeks post-infection while H) shows a representative dot plot of PD-1 staining at 2 weeks 
post-infection. I) shows perforin and granzyme B staining in an unstimulated lung sample at 4 
weeks post-infection.  
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Supplementary Figure 3 IFN- secretion and degranulation are carried out by distinct 
populations of cells in lung. 
Percent IFN-+ and CD107+ cells during primary infection (A and B) and secondary (C and D) 
infection. A) and C) are GAP, B) and D) are ova. The data are mean ± SEM of 4 mice per time-
point.  
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Supplementary Figure 4 IFN- secretion and degranulation are carried out by distinct 
populations of cells in lymph node. 
Percent IFN-+ and CD107+ cells during primary infection (A and B) and secondary (C and D) 
infection. A) and C) are GAP, B) and D) are ova. The data are mean ± SEM of 4 mice per time-
point.  
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Supplementary Figure 5 ELISpot assay measuring M. tuberculosis-specific secretion of 
IFN- by T cells in the lungs. 
Cells were incubated with M. tuberculosis-infected DC for 48 hours. There was no background 
level of IFN- secretion, measured by incubating cells with either T cell media or unpulsed, 
uninfected DC (data not shown). Data are mean ± SEM of 4 mice per time-point.  
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APPENDIX B - A LIST OF MANUSCRIPTS IN PREPARATION 
1. Einarsdottir, T. and Flynn, J. L. Priming of Multifunctional CD4 and CD8 T Cells During M. 
tuberculosis Infection in Mice. (in preparation). 
2. Einarsdottir, T. and Flynn, J. L. Memory Cells Influence the Number and Quality of New CD8 
T Cells During Mycobacterium tuberculosis-ova Infection. (in preparation). 
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